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A B S T R A C T
Background
Topical corticosteroids are the most frequently prescribed dermatological treatment and are often used by pregnant women with skin
conditions. However, little is known about their safety in pregnancy.
Objectives
To assess the effects of topical corticosteroids on pregnancy outcomes in pregnant women.
Search methods
This is an update of a review previously published in 2009. We updated our searches of the following databases to July 2015: the
Cochrane Skin Group Specialised Register, the Cochrane Pregnancy and Childbirth Group Specialised Register, the Cochrane Central
Register of Controlled Trials (CENTRAL) (2015, Issue 6), MEDLINE, EMBASE, and LILACS. We also searched five trials registers
and checked the reference lists of included studies, published reviews, articles that had cited the included studies, and one author’s
literature collection, for further references to relevant RCTs.
Selection criteria
Randomised controlled trials and cohort studies of topical corticosteroids in pregnant women, as well as case-control studies comparing
maternal exposure to topical corticosteroids between cases and controls when studies reported pre-specified outcomes. The primary
outcomes included mode of delivery, major congenital abnormality, birth weight, and preterm delivery (delivery before 37 completed
weeks gestation); the secondary outcomes included foetal death, minor congenital abnormality, and low Apgar score (less than seven at
5 min).
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Two authors independently applied selection criteria, extracted
data, and assessed the quality of the included studies. A third author was available for resolving differences of opinion. A further author
independently extracted data from included studies that were conducted by authors of this systematic review.
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Main results
We included 7 new observational studies in this update, bringing the total number to 14, including 5 cohort and 9 case-control studies,
with 1,601,515 study subjects.
Most studies found no causal associations between maternal exposure to topical corticosteroids of any potency and pregnancy outcomes
when compared with no exposure. These outcomes included: mode of delivery (risk ratio (RR) 1.04, 95% confidence interval (CI)
0.95 to 1.15, 1 cohort study, n = 9904, low quality evidence); congenital abnormalities, including orofacial cleft or cleft palate and
hypospadias (where the urethral opening is on the underside of the penis) (RR 0.82, 95% CI 0.34 to 1.96, 2 cohort studies, n = 9512,
low quality evidence; and odds ratio (OR) 1.07, 95% CI 0.71 to 1.60, 1 case-control study, n = 56,557); low birth weight (RR 1.08,
95% CI 0.86 to 1.36; n = 59,419, 4 cohort studies; very low quality evidence); preterm delivery (RR 0.93, 95% CI 0.81 to 1.08, 4
cohort studies, n = 59,419, low quality evidence); foetal death (RR 1.02, 95% CI 0.60 to 1.73, 4 cohort studies, n = 63,885, very low
quality evidence); and low Apgar score (RR 0.84, 95% CI 0.54 to 1.31, 1 cohort study, n = 9220, low quality evidence).
We conducted stratified analyses of mild or moderate potency, and potent or very potent topical corticosteroids, but we found no
causal associations between maternal exposure to topical corticosteroid of any potency and congenital abnormality, orofacial clefts,
preterm delivery, or low Apgar score. For low birth weight, although the meta-analysis based on study-level data was not significant
for either mild to moderate corticosteroids (pooled RR 0.90, 95% CI 0.74 to 1.09, 3 cohort studies, n > 55,713) or potent to very
potent corticosteroids (pooled RR 1.58, 95% CI 0.96 to 2.58, 4 cohort studies, n > 47,651), there were significant differences between
the two subgroups (P = 0.04). The results from three of the individual studies in the meta-analysis indicated an increased risk of low
birth weight in women who received potent to very potent topical corticosteroids. Maternal use of mild to moderate potency topical
steroids was associated with a decreased risk of foetal death (pooled RR 0.70, 95% CI 0.64 to 0.77, 2 studies, n = 48,749; low quality
evidence), but we did not observe this effect when potent to very potent topical corticosteroids were given during pregnancy (pooled
RR 1.14, 95% CI 0.69 to 1.88, 3 studies, n = 37,086, low quality evidence).
We used the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) Working Group approach to rate the
overall quality of the evidence. Data from observational studies started at low quality. We further downgraded the evidence because of
imprecision in low birth weight and inconsistency in foetal death. Lower quality evidence resulted in lower confidence in the estimate
of effect for those outcomes.
Authors’ conclusions
This update adds more evidence showing no causal associations between maternal exposure to topical corticosteroids of all potencies
and pregnancy outcomes including mode of delivery, congenital abnormalities, preterm delivery, foetal death, and low Apgar score,
which is consistent with the previous version of this review. This update provides stratified analyses based on steroid potency; we
found no association between maternal use of topical corticosteroids of any potency and an increase in adverse pregnancy outcomes,
including mode of delivery, congenital abnormality, preterm delivery, foetal death, and low Apgar score. Similar to the previous version
of the review, this update identified a probable association between low birth weight and maternal use of potent to very potent topical
corticosteroids, especially when the cumulative dosage of topical corticosteroids throughout the pregnancy is very large, which warrants
further investigation. The finding of a possible protective effect of mild to moderate topical corticosteroids on foetal death could also
be examined.
P L A I N L A N G U A G E S U M M A R Y
Safety of topical steroids in pregnancy
Review question
Is it safe to use topical steroids (steroid creams or ointments) in pregnancy?
Background
Topical steroids are the most commonly used medicines for skin conditions. Pregnant women may need topical steroids to treat skin
conditions, but it is unclear if they are safe or harmful during pregnancy.We aimed to examine the safety of topical steroids in pregnancy.
Study characteristics
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Weupdated the review that was previously published in 2009. We examined the research published up to July 2015 and found seven new
studies. All in all, this updated review included a total of 14 observational studies that assessed 1,601,515 pregnancies. Observational
studies are generally regarded as less rigorous than randomised controlled clinical trials. The funding source was from academic or
governmental institutions in 10 studies and was not reported in 4 studies.
Key results
We found no associations between mothers’ use of topical steroids of any potency and type of delivery, birth defects, premature births,
or low Apgar score.
There is some evidence indicating a relation between low birth weight and maternal use of potent or very potent topical steroids,
especially when high doses are used in pregnancy, and this may warrant more research. On the other hand, maternal use of mild or
moderate topical corticosteroids is not related to low birth weight. We even found that mild or moderately potent topical steroids
protect against death of the baby, but this was not seen when the mothers used potent or very potent topical steroids. This finding
needs further examination.
Quality of evidence
The overall quality of evidence is low because all available studies were observational. The high quality study design of the randomised
controlled trial that allocates participants to receive either topical corticosteroids or no treatment is not generally feasible in pregnant
women due to ethical concerns about possible exposure of the foetus to an experimental treatment.
Where we further downgraded the quality of the evidence to ’very low’, it was because we had detected variation in the results from
the studies that we found, which means that we have low confidence in our estimates of the effects for our outcomes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topical corticosteroids compared with no topical corticosteroids for pregnant women
Participants or population: pregnant women
Settings: ranging from single hospital to multinational congenital abnormality register
Intervention: topical corticosteroids
Comparison: no topical corticosteroids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Unexposed
group (in cohort study)
/control group (in case-
control study)
Exposed group (in co-
hort study)/case group
(in case-control study)
Mode of delivery (risk
for either assisted or ce-
sarean delivery)
18.29% 18.89% RR 1.04, 95% CI 0.95 to
1.15
9904 (1 cohort study) ++OOa
low
Only 1 study (Chi 2013)
provided detailed data
Congenital abnormality Cohort studies: 3.58% in
the unexposed group
Case-control study: 0.
17% in the control group
Cohort studies: 2.94% in
the exposed group
Case-control study: 0.
18% in the control group
Cohort studies: RR 0.82,
95% CI 0.34 to 1.96
Case-control study: OR 1.
07, 95% CI 0.71 to 1.60
9433 (1 cohort study)
; 56,557 (1 case-control
study)
++OOa
low
The RR in 1 cohort study
(Mahé 2007) was not es-
timable due to no events
in either the exposed or
unexposed group
Orofacial cleft Cohort studies: incidence
of orofacial cleft ranged
from 0.10% to 0.16%
Case-con-
trol studies: prevalence of
exposure ranged across
the control groups from
0.19% to 18.75%
Cohort studies: incidence
of orofacial cleft ranged
from 0.13% to 0.21%
Case-control studies:
prevalence of exposure in
the case groups was 0.
04% to 1.72%
Cohort studies: RR 1.12,
95% CI 0.54 to 2.33
Case-control studies: OR
1.20, 95% CI 0.68 to 2.
13
40,605 (2 cohort studies)
; 641,917 (8 case-control
studies)
++OOa
low
Consistent results except
1 case-control with a high
risk of bias
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Low birth weight Cohort studies: 0.16% to
10.71%
Cohort studies: 0.18% to
30.43%
RR 1.08, 95% CI 0.86 to
1.36
59,419 (4 cohort studies) +OOOb
very low
3 studies showed an in-
creased risk of low birth
weight in those who re-
ceived potent or very
potent topical corticos-
teroids
Preterm delivery Cohort studies: 0.76% to
6.40%
Cohort studies: 0% to 6.
61%
RR 0.93, 95% CI 0.81 to
1.08
59,419 (4 cohort studies) ++OOa
low
-
Foetal death Cohort studies: 0% to 9.
27%
Cohort studies: 0% to 7.
11%
RR 1.02, 95% CI 0.60 to
1.73
63,885 (4 cohort studies) +OOOc
very low
-
Low Apgar score Cohort study: 0% to 1.
30%
Cohort study: 0% to 1.
06%
RR 0.84, 95% CI 0.54 to
1.31
9,220 (1 cohort study) ++OOa
low
-
*The basis for the assumed risk is the prevalence of the outcome in the control group. The corresponding risk is based on the assumed risk in the comparison group and the relative effect
of the intervention (and its 95% CI).
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate
RR: risk ratio; OR: odds ratio; CI: Confidence interval.
a The default level of the quality of the evidence for observational studies is low.
bDowngraded one level due to imprecision.
cDowngraded one level due to inconsistency.
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B A C K G R O U N D
Description of the intervention
Corticosteroids have four pharmacological properties: they cause
constriction of blood vessels and decrease cell proliferation,
immunosuppression, and anti-inflammatory effects (Baumann
1999). Topical corticosteroids are the most frequently prescribed
dermatologic treatment and are often preferred to systemic cor-
ticosteroids because they are assumed to be associated with less
systemic effects (Baumann 1999). Topical corticosteroids are the
principal therapy for eczematous dermatoses (Berth-Jones 2004),
and they are also effective in treating inflammatory dermatoses
such as discoid lupus erythematosus (Jessop 2000), bullous pem-
phigoid (Khumalo 2005), and chronic palmoplantar pustulosis
(Marsland 2006). Women with these chronic dermatoses may
continuously need a topical corticosteroid during pregnancy.
Moreover, women with specific dermatoses of pregnancy, e.g.,
atopic eruption of pregnancy, polymorphic eruption of pregnancy,
and pemphigoid gestationis, also require topical corticosteroids
(Ambros-Rudolph 2006). However, little is known about the ef-
fects of topical corticosteroids on the foetus.
The maternal skin conditions in pregnancy where topical corti-
costeroids are required may be classified into two main categories
according to their pathological mechanism.
1. Autoimmune dermatoses such as autoimmune bullous
dermatoses, in particular pemphigoid gestationis and lupus
erythematosus.
2. Immunological and inflammatory dermatoses such as
atopic eruption of pregnancy, polymorphic eruption of
pregnancy, seborrhoeic dermatitis, and psoriasis.
In general, the aforementioned maternal skin conditions do not
affect pregnancy outcomes, although pemphigoid gestationis is
associated with an increase in small-for-gestational-age children
(Ambros-Rudolph 2006), and systemic lupus erythematosus is as-
sociated with an increase in preterm delivery, foetal growth re-
striction, and stillbirth (Cunningham 2005). The Apgar score is
a measure of the physical condition (breathing, heart rate, muscle
tone, reflexes and skin colour) of newborns shortly after birth; a
score of less than seven at 5 min is a poor indicator of survival
(Casey 2001).
How the intervention might work
Studies have shown that corticosteroids cause birth defects and
other adverse effects of the foetus in animals. Systemic corticos-
teroids induced cleft palate in rabbits, mice, rats, and hamsters
(Nanda 1970; Nasjleti 1967; Shah 1976; Walker 1967). The in-
cidence of sex organ defects in mice correlated with the dose of
corticosteroids applied topically to the eyes (Ballard 1977). In ju-
venile rhesus monkeys, prenatal administration of dexamethasone
caused a permanent loss of hippocampal neurons and an eleva-
tion of baseline and poststress cortisol concentrations in the blood
(Uno 1994). Prenatal administration of one to four doses of be-
tamethasone 0.5 mg per kg at 7-day intervals, starting from three
weeks before delivery, reduced the birth weight of lambs by 15%
after one dose, 19% after two doses, and 27% after three and four
doses (Ikegami 1997).
Whether systemic corticosteroid exposure in humans is teratogenic
is controversial, and conflicting reports have appeared in the liter-
ature over the last two decades. A population-based case-control
study of 662 infants with orofacial cleft and 734 controls showed
that systemic corticosteroid use during the periconceptional pe-
riod was associated with orofacial cleft (Carmichael 1999). An-
other case-control study on 1184 infants with non-syndromic oro-
facial cleft (i.e., orofacial cleft without associated congenital mal-
formations, believed to be caused by multifactorial environmental
and genetic factors with a low risk of familial occurrence; Edwards
2003) also showed a significant association between first trimester
exposure to systemic corticosteroids and cleft lip (Rodriguez-Pinil
1998). By contrast, a cohort study did not find significant differ-
ences in the incidence of major anomaly between 111 infants of
mothers with first trimester exposure to systemic corticosteroids
and 172 unexposed infants (Park-Wyllie 2000). Another cohort
study comparing 311 exposed and 790 non-exposed women de-
tected no significant differences in the rates of major anomalies,
non-genetic major anomalies, or congenital heart defects (Gur
2004). Nevertheless, both studies found a lowered gestational age
at delivery, an increase in preterm delivery, and reduced birth
weight in the exposed group (Gur 2004; Park-Wyllie 2000).
The systemic effects of topical corticosteroids depend largely on
the extent of skin absorption, which varies from 0.7% to 7%
through intact skin (Sifton 2002).However, topical corticosteroids
are often prescribed for inflammatory dermatoses, where the skin
barrier is disrupted and skin absorption is enhanced. This could
possibly lead to systemic effects and might have an impact on the
foetus (Chi 2011b). The absorption from hydrocortisone cream
1% during exacerbation of atopic dermatitis was 11 to 31 times
that in remission (Turpeinen 1988). Although hydrocortisone
is the weakest corticosteroid, skin application of hydrocortisone
cream 1% beyond one month was shown to suppress the adrenal
glands in people with severe skin disease (Turpeinen 1989). Clo-
betasol propionate ointment 0.05%, the most potent topical cor-
ticosteroid available, can cause adrenal suppression at doses as low
as 2 g per day for one week (Sifton 2002).
The foetotoxic effects of corticosteroids depend on their ability
to cross the placenta (Chi 2011b). The principal enzyme that
metabolises corticosteroids is 11-beta-hydroxysteroid dehydroge-
nase-2, or 11βHSD2 (Sun 1998). This enzyme converts the ac-
tive form cortisol (also known as hydrocortisone) to biologically
inactive cortisone, acting as a barrier in pregnancy and protecting
the foetus from potential harm by regulating the amount of ma-
ternal cortisol that passes through the placenta to reach the foetal
6Safety of topical corticosteroids in pregnancy (Review)
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compartment (Sun 1998). Based on the weak potency and high
metabolism in the placenta, hydrocortisone is often presumed safe
in pregnancy (Chi 2011b). However, a human study on maternal-
foetal cortisol transfer conducted before abortion illustrated that
15% of 3H-cortisol passed through the placenta without being
metabolised (Murphy 1974). Another human study demonstrated
a linear relationship between maternal and foetal serum cortisol
levels (Gitau 1998; Gitau 2001). Therefore, administration of hy-
drocortisone in pregnancy may still affect the foetus.
The ability to cross the placental barrier varies among other
corticosteroids. Only 10% to 13% of prednisolone crosses the
placenta to reach the foetus (Beitins 1972). By contrast, be-
tamethasone, methylprednisolone, and dexamethasone are much
less metabolised by 11βHSD2: around 30%, 45%, and 67%
cross the placenta, respectively (Anderson 1981; Ballard 1975;
Petersen 1980; Smith 1988). Fluticasone and budesonide are not
metabolised by placental 11βHSD2 (Murphy 2007) and there-
fore cross the placenta unhindered.
To the best of our knowledge, there are no human studies eval-
uating the amounts of topical corticosteroids that reach the foe-
tus after topical application, but animal studies have found that
corticosteroids are present in the foetal blood after topical appli-
cation. Considerable amounts of betamethasone 17,21-dipropi-
onate appeared in the foetal blood of mice and rabbits after topical
application to their mothers’ skin (Yamada 1981). Furthermore,
corticosteroids are teratogenic not only through systemic adminis-
tration but also through topical application in animals. For exam-
ple, diflorasone diacetate cream induced cleft palate when applied
topically to the chest skin of pregnant rats at a dose of 0.001 mg
per kg per day, which is about 30% of the human topical dose.
When the application dose was increased to 0.5 mg per kg per
day, the treated rats had a higher rate of foetal death than the
untreated controls (Taro 1999). Rabbits receiving a topical dose
of diflorasone diacetate 0.016 mg per kg per day had depressed
foetal growth, external anomalies (31.9%), cleft palate (22.2%),
and visceral defects (45.5%) (Narama 1984).
Around 40 topical corticosteroids are commercially available
(Baumann 1999; Berth-Jones 2004; Hengge 2006; Mehta 2006).
The aforementioned variations in placental metabolism and their
differences in potency and skin absorption suggest that they may
have varying degrees of adverse effects on the mother and foetus.
Why it is important to do this review
Treatment decisions are almost always a trade-off between poten-
tial benefit and harm. Lack of information and clarity about the
risk of topical corticosteroids increases therapeutic uncertainty and
often results in under-prescribing, even in situations when treat-
ment is required and considered safe for use in pregnancy (Chi
2011b). On the other hand, many people are excessively nervous
about the adverse effects of corticosteroids anyway. ’Steroid pho-
bia’ may be increased during pregnancy because of concerns for
possible foetal harm, resulting in unnecessary suffering in preg-
nant women due to under-treatment (Chi 2011b). Thus, there is
a need for clear guidance.
Pharmacology references such as the British National Formulary
and Thompson Micromedex do not give specific advice on pre-
scribing topical corticosteroids for pregnant women (Mehta 2006;
ThomsonHealthcare 2009). Topical corticosteroids are often only
labelled in the prescribing information as “should be used during
pregnancy only if the potential benefit justifies the potential risk
to the foetus” (GlaxoSmithKline 2002; Schering 2003). A gen-
eral assumption is that use of low-potency topical corticosteroids,
like hydrocortisone, is safe during pregnancy, but this may be ill-
founded. On the other hand, despite the lack of sufficient safety
data, some women still use topical corticosteroids during preg-
nancy; a survey of the UK General Practice Research Database
showed that over 3% of 81,975 pregnant women had been pre-
scribed a topical corticosteroid during early pregnancy (Hardy
2006).
Thus, a systematic review of the safety of topical corticosteroid
use during pregnancy is required to bring together the relevant ev-
idence for people wishing to make a well-informed decision. This
review aimed to summarise the best evidence of adverse perinatal
effects of topical corticosteroids. We did not consider other as-
pects of the safety of topical corticosteroids, for example their local
and systemic adverse effects, as they are not specific to pregnant
women.
A previous version of this review included seven observational
studies (Chi 2009). The data available at that time were limited
and inconclusive, failing to detect an association between topical
corticosteroids and congenital abnormality, preterm delivery, or
stillbirth, but the findings suggested an association of very potent
topical corticosteroids with lowbirth weight.We therefore decided
to update this review to take into account new evidence that has
emerged.
O B J E C T I V E S
To assess the effects of topical corticosteroids on pregnancy out-
comes in pregnant women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Owing to ethical concerns, randomised controlled trials (RCTs) of
drugs are not carried out in pregnant women for fear of maternal
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exposure to an experimental drug that may harm the foetus, unless
the clinical trial focuses on a pregnancy-related condition such as
labour induction (Meadows 2001). Therefore, when we started
working on this review, we expected that there would be few or
no RCTs of topical corticosteroid use in pregnant women. Fur-
thermore, although RCTs are the gold standard for investigating
the effects of interventions, they are not a good tool for detecting
adverse outcomes that are rare, prone to occur in a specific group
of people, or take a long time to develop (Higgins 2011). This
review therefore included cohort and case-control studies as well.
The inclusion criteria for each type of study were as follows.
1. All RCTs that exclusively recruited pregnant women, tested
topical corticosteroids during pregnancy, and reported pregnancy
outcomes or adverse events. We did not include RCTs that
recruited pregnant women only as a subset.
2. All cohort studies that evaluated pregnancy outcomes or
adverse events after exposure to topical corticosteroids in
pregnancy. We included both prospective and retrospective
cohort studies.
3. All case-control studies that compared exposure to topical
corticosteroids during pregnancy between cases with any of the
outcomes of interest and the control group.
Types of participants
Any pregnant women with a skin condition requiring topical cor-
ticosteroid treatment.
Types of interventions
1. In RCTs: If we had found relevant RCTs, the intervention
group would have received one or more topical corticosteroids
during pregnancy. The comparators would have been placebo,
no treatments, or any treatments other than corticosteroids (e.g.,
topical emollients, other non-corticosteroid topical medicines,
and oral antihistamines). If we had analysed the effects on
congenital abnormality by topical corticosteroids, the
intervention group would have been restricted to women who
received topical corticosteroids in the first trimester of gestation.
2. In cohort studies: The exposed group received one or more
topical corticosteroids during pregnancy. The unexposed group
was composed of either pregnant women with a skin condition
not exposed to topical corticosteroids or pregnant women from
the general population not exposed to topical corticosteroids.
When we analysed the effects of topical corticosteroids on
congenital abnormality, the exposed group was restricted to
women who received topical corticosteroids in the first trimester
of gestation.
3. In case-control studies: The case group consisted of any
women and their children with any of the outcomes of interest.
The control group consisted of any women and their children
without that outcome. Some case-control studies of congenital
abnormality may have used a control group consisting of
children with congenital abnormalities other than the
abnormality of interest. If the comparison congenital
abnormalities resulted from a similar embryo-pathological
mechanism to the abnormality of interest, we excluded such
studies. When assessing the effects of topical corticosteroids on
congenital abnormality, we only compared maternal exposure to
topical corticosteroids in the first trimester of gestation between
the two groups.
Types of outcome measures
Primary outcomes
Maternal outcomes
Mode of delivery: normal vaginal delivery, assisted delivery, or
cesarean section.
Outcomes in children
1. Major congenital abnormality: structural-morphological
birth defect that is either fatal or causing handicap or death if
untreated (Czeizel 2005)
2. Outcomes related to foetal growth: birth weight, body
length, foetal growth restriction, or other
3. Preterm delivery (delivery before 37 completed weeks’
gestation)
Secondary outcomes
1. Foetal death
2. Mild congenital abnormality: structural-morphological
birth defect requiring medical intervention but with good life
expectancy, such as congenital dislocation of the hip or
undescended testis (Czeizel 2005)
3. Apgar score < 7 at 5 min (Casey 2001)
Timing of outcome assessment
In RCTs and cohort studies, the follow-up had to be long enough
for the outcomes to develop, be measured, and be recorded. Mode
of delivery, foetal growth-related measures, preterm delivery, and
low Apgar score are amenable to assessment immediately after
birth. By contrast, congenital abnormalities may not be diagnosed
or recorded until some time has passed. We thus included all rel-
evant studies irrespective of the length of follow-up, but we ad-
dressed the length of follow-up of the children when assessing the
methodological quality of the studies on congenital abnormality.
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Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, or in progress).
Electronic searches
For this update, we revised the search strategies for the Skin
Group Specialised Register, CENTRAL, MEDLINE, EMBASE,
and LILACS. We searched the following databases up to 9 July
2015.
• The Cochrane Skin Group Specialised Register, using the
search strategy in Appendix 1.
• The Cochrane Pregnancy and Childbirth Group Specialised
Register, by contacting the Trials Search Co-ordinator (searched
to July 2013). The topic list was used for searching as described
in Appendix 2.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (2015, Issue 6), using the strategy in Appendix 3.
• MEDLINE via Ovid (from 1946) using the strategy in
Appendix 4.
• EMBASE via Ovid (from 1974) using the strategy in
Appendix 5.
• LILACS (Latin American and Caribbean Health Sciences
Information Database, from 1982) using the strategy in
Appendix 6.
In MEDLINE we searched for cohort and case-control studies as
well as RCTs, using the BMJ Clinical Evidence filter available at
http://www.york.ac.uk/inst/crd/intertasc/observational.htm (see
Appendix 4). In LILACS we searched for cohort, case-control,
and controlled clinical trials, using the filters available within the
database.
We also searched the following trials registers on 10 July 2015
using the terms ’pregnancy’,’pregnant’, ’topical steroid’ and ’topical
corticosteroid’.
• The ISRCTN registry (www.controlled-trials.com), using
the strategy in Appendix 7.
• The US National Institutes of Health Ongoing Trials
Register (clinicaltrials.gov), using the strategy in Appendix 8.
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au), using the strategy in Appendix 9.
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch), using the
strategy in Appendix 10.
• The EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/), using the strategy in Appendix 11.
Searching other resources
Handsearching
We handsearched the literature collection of one author (CC) on
10 July 2015.
Reference lists
We scanned the bibliographies of the included studies and pub-
lished reviews for relevant references. We also used SCI-EX-
PANDEDon21 July 2014 to identify the articles that had cited the
included studies and scanned for further relevant studies. When
we updated our search for this review on 10 July 2015, our insti-
tution no longer had a subscription to SCI-EXPANDED, so we
could not update the citation lists.
Correspondence
We planned to correspond with the original researchers to identify
unpublished or ongoing trials and observational studies.
Data collection and analysis
Some parts of the Methods section of this review use text that
was originally published in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We included ’Summary
of findings’ tables in our review to summarise the essential primary
and secondary outcomes and assessed the quality of the body of
evidence using the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias).
Selection of studies
Two authors (CC and SW) independently checked all the titles
and abstracts identified from the searches. If it was clear that the
study did not refer to a study on the use of topical corticosteroids
in pregnant women, we excluded it. The same two authors inde-
pendently assessed the full-text version of each remaining study
to determine whether it met the pre-defined selection criteria. We
resolved any differences in opinion through discussion within the
review team. We listed excluded studies in the Characteristics of
excluded studies tables after having read the full text.
Data extraction and management
Two authors (CC and SW) independently extracted the data using
a specially designed data extraction form. A third team member
(FW) was available for resolving any differences of opinion.
Assessment of risk of bias in included studies
RCTs
If we had found relevant RCTs, we would have evaluated the
following components that have been shown to result in biased
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estimates of intervention effects and recorded them in the ’Risk
of bias’ tables in the Characteristics of included studies (Higgins
2011).
1. The method of randomisation sequence generation.
2. The method of allocation concealment; we would have
judged ’adequate’ if the assignment was sufficiently
unpredictable.
3. Blinding of participants and investigators.
4. Blinding of outcome assessors.
5. Incomplete outcome data: we would have assessed how
many participants were lost to follow up in each arm, whether
the reasons for the losses were adequately reported, and whether
all participants were analysed in the groups to which they were
originally randomised (intention-to-treat principle).
6. Selective reporting: we would have assessed the possibility
of selective outcome reporting.
7. Other sources of biases: we would have assessed:
i) the maternal skin conditions for which topical
corticosteroids were required and the degree of certainty that the
women had a skin condition;
ii) the baseline assessment of the participants for age,
duration of disease, location involved, and severity of the skin
condition(s);
iii) drug identity, source, dose, duration of treatment, and
adequacy of instructions;
iv) whether the outcome measures were described and
their assessment was standardised;
v) whether previous treatments for skin conditions were
discontinued;
vi) whether concomitant treatments for skin conditions
were permitted or standardised;
vii) the use and appropriateness of statistical analyses,
where tabulated data could not be extracted from the original
publication.
Non-randomised studies
We used the Newcastle-Ottawa Scale (NOS) (Wells 2006) only as
a checklist to describe quality to provide the readers with a better
understanding of the diverse methods used. Below, we summarise
the considerations relevant to cohort and case-control studies.
Cohort studies
1. Representativeness of the exposed cohort (including
method of recruitment, clinical setting, and proportion of
eligible mothers or children recruited)
2. Selection of the unexposed cohort
3. Ascertainment of exposure to topical corticosteroids (e.g.,
how the exposure was defined and whether over-the-counter
topical corticosteroids were available)
4. Demonstration that outcome of interest was not present at
start of study
5. Comparability of the cohorts (control for potential
confounders, e.g., maternal skin condition, comorbidity,
maternal age, smoking and drinking habit, family history of
congenital abnormality, exposure to other medications, and
socioeconomic status)
6. Assessment of the outcomes
7. Sufficient length of the follow-up for outcomes to occur
8. Adequacy of the follow-up of the cohorts
Case-control studies
1. Adequacy of the case definition
2. Representativeness of the cases
3. Selection of the controls (including method of recruitment
and source)
4. Definition of the controls
5. Comparability of the cases and controls (control for
potential confounders, e.g., maternal skin condition,
comorbidity, maternal age, smoking and drinking habit, family
history of congenital abnormality, exposure to other
medications, and socioeconomic status)
6. Ascertainment of exposure to topical corticosteroids (e.g.,
how the exposure was defined and whether over-the-counter
topical corticosteroids were available)
7. Standard and valid method of ascertainment of exposure for
the cases and controls
8. Non-response rate
Measures of treatment effect
Dichotomous data
For dichotomous outcomes in RCTs (if found) and cohort studies,
we expressed the results as risk ratios (RR) and 95% confidence
intervals (CI). We expressed dichotomous outcomes in case-con-
trol studies as odds ratios (OR) and 95% CIs. We expressed the
results as ’number needed to treat for an additional harmful out-
come (NNTH)’ where appropriate for a range of plausible control
event rates.
Continuous data
We expressed continuous outcomes as mean difference (MD) and
95% CIs.
Unit of analysis issues
The study subjects in the included studies were the unit of analysis.
For the following types of studies, we would have used appropriate
analytical techniques, and we would not have pooled these studies
with studies of other designs.
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Cluster-randomised trials
We would have used the technique described in Chapter 16.3
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Cross-over trials
We excluded cross-over RCTs.
Studies with multiple treatment groups
If a study contained multiple intervention groups, we would have
made pair-wise comparisons of topical corticosteroids of similar
potency or active components versus no treatments, placebo, treat-
ments other than topical corticosteroids, or another topical corti-
costeroid.
Dealing with missing data
We contacted the investigators or funders for missing data when
the studies were published in the previous 15 years. When par-
ticipants dropped out, and the trialists adopted the per-protocol
analysis, we would have used the intention-to-treat analysis to re-
calculate the results.
Assessment of heterogeneity
We assessed the heterogeneity of studies with different designs (i.e.,
RCTs, cohort studies, and case-control studies) separately.Weused
the I2 statistic in examining the statistical heterogeneity. If the I2
statistic was less than 80% with reasonable clinical homogeneity,
we applied meta-analysis techniques as appropriate.
Assessment of reporting biases
We assessed the reporting biases of studies with different designs
separately. We planned to test publication bias by using a funnel
plot when adequate data were available for topical corticosteroids
of similar potency or for a similar active component.
Data synthesis
For studies with topical corticosteroids of similar potency or active
components, we conducted a meta-analysis to calculate a weighted
treatment effect across trials using a random-effects model.
Subgroup analysis and investigation of heterogeneity
We discussed issues of heterogeneity, such as study design, selec-
tion of the control group in case-control studies, maternal skin
condition and severity, maternal comorbidity, similarities and dif-
ferences in the types of interventions. We performed further sub-
group analyses where adequate data were available.
The originally planned subgroups were different maternal skin
conditions (polymorphic eruption of pregnancy, pemphigoid ges-
tationis, etc.) and maternal ages as described by the original re-
searchers. However, these data were unavailable.
As we expected, the risk of adverse effects of topical corticosteroids
may be related to the strength, so for this update we conducted a
subgroup analysis based on corticosteroid potency (mild to mod-
erate versus potent to very potent), as defined by the British Na-
tional Formulary (Mehta 2006); see Table 1.
Sensitivity analysis
We conducted a sensitivity analysis to examine the intervention
effects after excluding poor quality studies. We defined poor qual-
ity studies as those rated at a high risk of bias for one or more key
domains.
GRADE
We used the Grades of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) system to describe the quality of
the evidence and the strength of recommendation (GRADE 2013;
Guyatt 2011). GRADE has been adopted postprotocol to rate the
quality of evidence.We expressed the quality of evidence on a four-
point adjectival scale from ’high’ to ’very low’.We downgraded it if
there was unexplained, clinically important heterogeneity or if the
study methodology had a risk of bias, the evidence was indirect,
there was important uncertainty around the estimate of effect, or
there was evidence for publication bias. Therefore, it was possible
to grade the evidence at a very low quality if several of these con-
cerns were present.
Other
Where there was uncertainty, we contacted the original researchers
for clarification. A consumer (ED) worked with us to help ensure
the relevance and readability of the final review.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
As shown in Figure 1, our update searches identified 441 addi-
tional records. We screened out 431 references based on titles
and abstracts. Of the remaining 10 records, we excluded 4 (see
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Characteristics of excluded studies).We included 6 records report-
ing 7 new studies (one publication reporting 2 studies: Skuladottir
2014b; Skuladottir 2014c), along with 7 studies from the previous
review, bringing the total number of studies that we included in
the quantitative and qualitative analyses to 14.
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Figure 1. Study flow diagram.
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Included studies
We included 14 studies involving 1,601,515 study subjects.
In addition to the 7 studies included in the previous version of the
review (Carmichael 2007; Czeizel 1997; Edwards 2003; Källén
2003;Mahé 2007;Mygind 2002; Pradat 2003), we included7new
studies that met our inclusion criteria for this update (Carmichael
2009; Chi 2011a; Chi 2013; Hviid 2011; Skuladottir 2014a;
Skuladottir 2014b; Skuladottir 2014c).
Skuladottir 2014a was an extension of the Carmichael 2007 study
on orofacial cleft, with the latter reporting data collected from
1997 to 2002 and the former reporting those collected from 2003
to2009.Carmichael 2009 used the same data source asCarmichael
2007 and Skuladottir 2014a, but it examined another outcome
(hypospadias) usingdata collected from1997 to2004.Wedescribe
the details of the 14 included studies in the Characteristics of
included studies tables.
Design
Of the 14 included studies, 5 were cohort studies (Chi 2011a;
Chi 2013; Hviid 2011; Mahé 2007; Mygind 2002), and the
other 9 were case-control studies (Carmichael 2007; Carmichael
2009; Czeizel 1997; Edwards 2003; Källén 2003; Pradat 2003;
Skuladottir 2014a; Skuladottir 2014b; Skuladottir 2014c). The
original researchers reported the Skuladottir 2014c study as a co-
hort study; however, we judged it to be a case-control study after
examining the full text.
Sample size
The 5 cohort studies that we included (Chi 2011a; Chi 2013;
Hviid 2011; Mahé 2007; Mygind 2002) enrolled 35,503 women,
2658 women, 22,480 women, 28 women, and 363 women ex-
posed to topical corticosteroids during pregnancy, respectively.
However, the Mygind 2002 study did not report the respec-
tive number of women who received mild or moderate and po-
tent to very potent topical corticosteroids. We requested detailed
data from the original researchers of the Mahé 2007 study, but
they could only provide valid data for 23 exposed women for
analysis. Six of the included case-control studies (Carmichael
2007; Edwards 2003; Källén 2003; Skuladottir 2014a; Skuladottir
2014b; Skuladottir 2014c) enrolled 1769, 48, 1044, 2372, 573,
and 184 children with orofacial cleft, respectively. The other two
case-control studies (Czeizel 1997; Pradat 2003) enrolled 20,830
and 11,150 children with congenital abnormality, but only 1223
and 982 of them had orofacial cleft, respectively. The Carmichael
2009 study included 1165 children with moderate to severe hy-
pospadias.
Setting
The settings of the included studies ranged from a multina-
tional project (Pradat 2003) to a single country or local popu-
lation-based register (Carmichael 2007; Carmichael 2009; Chi
2011a;Chi 2013;Czeizel 1997;Hviid 2011;Källén2003;Mygind
2002; Skuladottir 2014a; Skuladottir 2014c) to a single hospital
(Edwards 2003; Mahé 2007; Skuladottir 2014b).
Study subjects
The study subjects in all of the included cohort studies (Chi2011a;
Chi 2013; Hviid 2011;Mahé 2007;Mygind 2002) were pregnant
women. In the Danish study (Mygind 2002), the study subjects
were restricted to primiparouswomen carrying a single foetus. The
cases of the included case-control studies had congenital abnormal-
ity, orofacial cleft, or hypospadias (Carmichael 2007; Carmichael
2009; Czeizel 1997; Edwards 2003; Källén 2003; Pradat 2003;
Skuladottir 2014a; Skuladottir 2014b; Skuladottir 2014c).
Interventions
The interventions in all included studies were topical corticos-
teroids. In the Senegalese study (Mahé 2007), the women used
very potent topical corticosteroids (predominantly clobetasol pro-
pionate, mean dosage: 600 g (range 120 to 1700) during the whole
pregnancy) for skin lightening. In Chi 2011a, 64.9% of the ex-
posed women received topical corticosteroids for steroid-respon-
sive dermatoses. The mean amounts of potent to very potent top-
ical corticosteroids prescribed during the whole pregnancy was
83.5 g (range 10 to 2800 g) and 64 g (range 15 to 490 g) in the
Chi 2011a and Chi 2013 studies, respectively. In two case-control
studies (Czeizel 1997; Edwards 2003), topical corticosteroids were
used mainly for allergic dermatoses such as urticaria and eczema.
In the Australian study (Edwards 2003), seven out of the nine
women in the case (orofacial cleft) group used potent topical corti-
costeroids.Only onewoman in the control group used hydrocorti-
sone, the weakest topical corticosteroid. The other nine studies did
not report the indications for topical corticosteroids (Carmichael
2007; Carmichael 2009; Hviid 2011; Källén 2003; Pradat 2003;
Mygind 2002; Skuladottir 2014a; Skuladottir 2014b; Skuladottir
2014c).
Outcomes
Due to the limitation of study design, the only outcome that
could be measured in all nine case-control studies was congenital
abnormality, orofacial cleft, or hypospadias (Carmichael 2007;
Carmichael 2009; Czeizel 1997; Edwards 2003; Källén 2003;
Pradat 2003; Skuladottir 2014a; Skuladottir 2014b; Skuladottir
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2014c). Investigators in only four cohort studies measured the
other outcomes, including mode of delivery, birth weight, preterm
delivery, stillbirth, and low Apgar score (Chi 2011a; Chi 2013;
Mahé 2007; Mygind 2002). The other cohort study, Hviid 2011,
only assessed orofacial cleft.
We analysed orofacial cleft separately, as it is an expected possible
associated outcome.When detailed data were available, we further
analysed the two categories of orofacial cleft, (i.e., cleft lip with or
without cleft palate, and isolated cleft palate), separately because
they are considered aetiologically distinct (Stanier 2004).
Edwards 2003 used a classification of orofacial cleft different from
ours and divided the cases as cleft palate ± lip and isolated cleft
palate (see Effects of interventions). We thus used the published
data to calculate the case number of cleft lip with or without
cleft palate and used Review Manager software (RevMan 2014) to
recalculate all the crude ORs and 95% CIs for consistency.
Excluded studies
We excluded four studies identified from searches after obtaining
the full text (see the Characteristics of excluded studies tables).
Studies awaiting assessment
We did not identify any studies that we could not classify.
Ongoing studies
We did not find any relevant ongoing studies.
Risk of bias in included studies
We present the summarised risk of bias across all included studies
in Figure 2 and the respective ’Risk of bias’ item for each included
study in Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Cohort studies
The 5 cohort studies were Chi 2011a, Chi 2013, Hviid 2011,
Mahé 2007, and Mygind 2002.
1. Representativeness of the exposed cohort: the setting of the
Mygind 2002 study was a local population, but investigators
only recruited primiparous women carrying a single foetus. The
setting of the Mahé 2007 study was a single maternity centre.
These settings limited the external validity of the studies. The
other three cohort studies used population-based data and thus
had a better generalisability (Chi 2011a; Chi 2013; Hviid 2011).
2. Selection of the unexposed cohort: all of the five included
cohort studies drew the unexposed cohort from the same source
as the exposed cohort so were judged at low risk of bias.
3. Ascertainment of exposure to topical corticosteroids: four
studies used record linkage to the prescription database (Chi
2011a; Chi 2013; Hviid 2011; Mygind 2002). However,
whether the women adhered to the prescribed corticosteroids
and whether they used over-the-counter topical corticosteroids
or topical corticosteroids from previous prescriptions or even
from their relatives or friends was unknown. The Senegalese
study used structured interviews (Mahé 2007). All were judged
at low risk of bias.
4. Demonstration that outcome of interest was not present at
start of study: all of the included cohort studies had a low risk of
bias for this item.
5. Comparability of the cohorts: Mygind 2002 controlled for
potential confounders, including maternal age and smoking, but
it did not assess potential confounding by indication. Though
Mahé 2007 and Hviid 2011 did not control for potential
confounders, they found no significant differences in the
potential confounders such as maternal socioeconomic and
education levels, age, and parity between women who used very
potent topical corticosteroids and those who did not. All of the
exposed women in the Mahé 2007 study used topical
corticosteroids for skin lightening. In the Chi 2011a and Chi
2013 studies, there were differences in potential confounders
between the exposed and control group, but these confounders
were adjusted in the statistical analyses.
6. Assessment of the outcomes: all of the included cohort
studies used record linkage to clinical records or birth registry
(Chi 2011a; Chi 2013; Hviid 2011; Mahé 2007; Mygind 2002).
None of them reported record validation for a sample of the
exposed women without the outcomes. In the Mygind 2002
study, the records of congenital abnormality in the register were
not entirely accurate. Among the five children registered as
having a congenital abnormality in the exposed group, two
actually did not have any abnormalities according to their
hospital records.
7. Sufficient length of the follow-up for outcomes to occur: all
studies had a sufficient length of follow-up until delivery or
foetal death (Chi 2011a; Chi 2013; Hviid 2011; Mahé 2007;
Mygind 2002).
8. Adequacy of the follow-up of the cohorts: Chi 2013, Hviid
2011, and Mygind 2002 had complete follow-up because the
records were from birth registries. In Mahé 2007, which was
prospective, 10 out of 99 (10.10%) women were lost to follow
up. The incidence of foetal growth restriction in Chi 2011a was
0.59%, which was lower than the usual reported rate of 3% to
7% (Romo 2009). The low incidence in Chi 2011a may have
reduced the statistical power leading to false-negative results;
however, this study found a significant association between
maternal exposure to potent or very potent topical
corticosteroids and foetal growth restriction.
Case-control studies
The 9 case-control studies were: Czeizel 1997; Edwards 2003;
Källén 2003; Pradat 2003; Carmichael 2007; Carmichael 2009;
Skuladottir 2014a; Skuladottir 2014b; Skuladottir 2014c.
1. Case definition: When assessing the teratogenic risk of
topical corticosteroids, the definition of the case varied among
the case-control studies that were included. Czeizel 1997 defined
a ’case’ as having an isolated congenital abnormality or
unidentified multiple congenital abnormalities, excluding those
with some mild congenital abnormalities, minor anomalies, or
congenital abnormality syndromes of known origin. Fourteen
congenital abnormality groups performed stratified analysis.
Edwards 2003 only included cases with non-syndromic orofacial
cleft. Skuladottir 2014a excluded cases of orofacial cleft that were
believed to be the result of another defect. On the other hand,
Källén 2003 and Skuladottir 2014c did not exclude cases with a
syndrome diagnosis. Carmichael 2007 and Skuladottir 2014b
included all cases of orofacial cleft in primary analyses and
excluded syndromic cleft in a sensitivity analysis. The
Malformation Drug Exposure Surveillance (MADRE) project
also included cases with multiple malformations, syndromes, and
even known causes like chromosomal defects (Pradat 2003).
Carmichael 2009 included cases of second- or third-degree
hypospadias.
2. Representativeness of the cases: The source of cases in six
studies was from a congenital malformation register (Carmichael
2007; Carmichael 2009; Czeizel 1997; Källén 2003; Pradat
2003; Skuladottir 2014a) and was limited to a cleft palate clinic
in Edwards 2003 and to two specialised surgical centres for
orofacial cleft in Skuladottir 2014b. In Skuladottir 2014c,
investigators identified cases with orofacial cleft through the
Medical Birth Registry of Norway. Pradat 2003 only included
children with congenital malformations and a positive history of
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maternal first trimester drug exposure, excluding children with
congenital malformations but without a history of maternal first-
trimester drug exposure; thus we judged it at unclear risk of bias
for this item.
3. Selection of the controls (including method of recruitment
and source): Czeizel 1997, Källén 2003, Skuladottir 2014b, and
Skuladottir 2014c selected the controls from a national birth
registry. Pradat 2003 selected controls from a multicentre
database, and Edwards 2003 used hospital controls. The NOS
considers that the use of hospital controls denotes an ’unclear’
risk of bias. In the Carmichael 2007, Carmichael 2009, and
Skuladottir 2014a studies, the controls without major congenital
malformations were randomly selected from birth certificates or
birth hospitals.
4. Definition of the controls: The controls were defined as
those without congenital abnormalities (Carmichael 2007;
Carmichael 2009; Czeizel 1997; Skuladottir 2014a; Skuladottir
2014b; Skuladottir 2014c) or without orofacial cleft (Edwards
2003; Källén 2003). In the Pradat 2003 study, the controls were
infants with congenital malformations other than orofacial cleft
and a history of maternal first-trimester drug intake.
5. Comparability of the cases and controls: Eight studies
controlled the potential confounders (Carmichael 2007;
Carmichael 2009; Czeizel 1997; Edwards 2003; Källén 2003;
Skuladottir 2014a; Skuladottir 2014b; Skuladottir 2014c).
Pradat 2003 used the MADRE database, which recruits children
with birth defects from many congenital abnormality registers
around the world; the researchers from this study treated the
children from the different registers as study subjects from
different studies and calculated the OR and 95% CI by using the
Mantel-Haenszel method to adjust the data that each register
provided about the study subjects.
6. Ascertainment of exposure to topical corticosteroids: In six
studies, investigators ascertained corticosteroid exposure
retrospectively by interviews (Carmichael 2007; Carmichael
2009; Edwards 2003; Pradat 2003; Skuladottir 2014a) or
questionnaire (Skuladottir 2014b). Czeizel 1997 used a prenatal
log book, questionnaire, and interview for ascertaining exposure.
In Källén 2003, midwives prospectively gathered data on drug
exposure (mainly in first trimester) at the first antenatal care visit
(usually week 10 to 12). In the Skuladottir 2014c study,
investigators also prospectively collected data on maternal drug
exposure using questionnaires completed at gestational weeks 15,
22, and 30.
7. Standard and valid method of ascertainment of exposure for
the cases and controls: All nine case-control studies used the
same ascertainment method for the cases and controls. However,
there was a 4.3 months’ delay in the interview of case mothers in
the Carmichael 2009 study.
8. Non-response rate: In the Australian study (Edwards 2003),
the non-response rate for the case and control groups was very
high at 70% and 85.8%, respectively. In the Hungarian study
(Czeizel 1997), the non-response rate was 18% and 35% for the
case and control groups, respectively. In the case group, regional
nurse visits to non-respondents decreased the non-response rate
by 10%. These two studies were judged at high risk of bias. In
Carmichael 2009, the non-response rate in the case group was
23%, but the exact non-response rate in the mothers of male-
only controls was not available. The non-response rate was
unavailable in six other studies (Carmichael 2007; Källén 2003;
Pradat 2003; Skuladottir 2014a; Skuladottir 2014b; Skuladottir
2014c).
Effects of interventions
See: Summary of findings for the main comparison Topical
corticosteroids compared with no topical corticosteroids for
pregnant women; Summary of findings 2Mild/moderate topical
corticosteroids versus no topical corticosteroids for pregnant
women; Summary of findings 3 Potent/very potent topical
corticosteroids compared with no topical corticosteroids for
pregnant women
We have addressed the effects of the interventions according to our
pre-specified outcomes. The interventions in all included studies
were topical corticosteroids.
Primary outcomes
Maternal outcomes
Mode of delivery
Of the included studies, only two cohort studies assessed themode
of delivery and found no significant differences between the ex-
posed and control groups (Chi 2013; Mahé 2007). Mahé 2007
did not provide exact statistics. Women who received topical cor-
ticosteroids during pregnancy did not have an increased risk for
either assisted or cesarean delivery (RR 1.04, 95%CI 0.95 to 1.15,
1 cohort study, n = 9904) in the Chi 2013 study (Analysis 1.1).
The quality of the evidence was rated as low for this outcome.
Outcomes in children
Congenital abnormality
We originally planned to analyse major and minor congenital ab-
normalities separately, but did not find any studies that reported
them separately. Therefore, we grouped the two outcomes to-
gether.
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Cohort studies
Only two cohort studies assessed this outcome (Mahé 2007;
Mygind 2002). One cohort study, Mygind 2002, did not find sig-
nificant differences in the risk for congenital abnormality between
women who received topical corticosteroids 30 days before con-
ception or during the first trimester and those who did not (RR
0.82, 95% CI 0.34 to 1.96, 1 cohort study, n = 9433; low quality
evidence; Analysis 1.2). Another cohort study, Mahé 2007 (n =
79), did not have any children with a congenital abnormality in
the exposed or unexposed groups (Analysis 1.2).
Case-control studies
One case-control study, Czeizel 1997, did not find significant dif-
ferences in maternal use of topical corticosteroids in the first three
months of gestation between children with 14 congenital abnor-
mality groups and their controls (OR 1.07, 95% CI 0.71 to 1.60,
n = 56,557; Analysis 1.3). We rated the quality of the evidence as
low.
Orofacial cleft
Cohort studies
Three cohort studies assessed orofacial cleft, its two categories, or
both (i.e., cleft lip with or without cleft palate and cleft palate
alone) (Chi 2011a; Chi 2013; Hviid 2011). We rated the quality
of evidence as low for orofacial cleft in the cohort studies.
• Orofacial cleft: Chi 2011a and Chi 2013 found no
associations between orofacial cleft and maternal exposure to
topical corticosteroids in the first 12 gestational weeks (pooled
RR 1.12, 95% CI 0.54 to 2.33, 2 studies, n = 40,605; Analysis
1.4).
• Cleft lip with or without cleft palate (Analysis 1.5): Neither
Chi 2011a nor Chi 2013 found any association between
maternal exposure to topical corticosteroids and cleft lip with or
without cleft palate (adjusted RR 1.20, 95% CI 0.40 to 3.61, n=
32,642; and 4.79, 95% CI 0.43 to 52.71, n = 7963, respectively).
Hviid 2011 found a link between maternal exposure to topical
corticosteroids in the first 12 gestational weeks and cleft lip with
or without cleft palate (adjusted RR 1.45, 95% CI 1.03 to 2.05,
n= 832,636); however, the study authors found no dose-response
nor potency-response relationship and concluded it to be a
spurious finding resulting from multiple comparisons. We thus
did not undertake a meta-analysis.
• Cleft palate alone: None of the three studies found any
associations between maternal exposure to topical corticosteroids
and cleft palate alone (pooled RR 1.31, 95% CI 0.82 to 2.11, 3
studies, n = 873,241; Analysis 1.6).
Case-control studies
Eight of the included case-control studies assessed this outcome
(Carmichael 2007; Czeizel 1997; Edwards 2003; Källén 2003;
Pradat 2003; Skuladottir 2014a; Skuladottir 2014b; Skuladottir
2014c). We rated the quality of the evidence for the outcome of
orofacial cleft as low for the case-control studies.
• Orofacial cleft (Analysis 1.7): One case-control study,
Edwards 2003, reported a significant association between
orofacial cleft and first-trimester use of topical corticosteroids
(adjusted OR 18.65, 95% CI 1.29 to 270.1, n = 106). However,
the other seven case-control studies found no such association.
The pooled OR was 1.20 (95% CI 0.68 to 2.13, 8 studies, n =
641,917).
• Cleft lip with or without cleft palate (Analysis 1.8): Edwards
2003 found a significant association between first-trimester use
of topical corticosteroids with cleft lip with or without cleft
palate (crude OR 13.57, 95% CI 1.50 to 123.05, n = 84), but
the other seven case-control studies did not. The pooled OR was
1.52 (95% CI 0.84 to 2.75, 8 studies, n = 639,654).
• Cleft palate alone (Analysis 1.9): Again, Edwards 2003
found significant associations between first-trimester use of
topical corticosteroids and cleft palate alone (crude OR 12.67,
95% CI 1.33 to 120.72, n = 80), unlike the rest of the case-
control studies. The pooled OR was 1.20 (95% CI 0.57 to 2.54,
8 studies, n = 637,450).
Hypospadias
One study, Carmichael 2009, only assessed this outcome, and we
thus decided to analyse it separately. Czeizel 1997 also reported
relevant data for this outcome. Both Carmichael 2009 and Czeizel
1997 found an associationbetweenhypospadias and first-trimester
use of topical corticosteroids (pooled OR 0.45, 95% CI 0.19 to
1.09, 2 studies, n = 42,618; Analysis 1.10). In our analyses, there
was limited or suggested evidence for an effect, although this did
not reach statistical significance.
Birth weight
A total of 4 cohort studies assessed low birth weight (i.e., birth
weight < 2500 g) or foetal growth restriction (defined as small-for-
dates, birth weight < 2500 g, or birth weight < 10th percentile)
(Chi 2011a; Chi 2013; Mahé 2007; Mygind 2002). When we ig-
nored the potency of corticosteroids, maternal exposure to topical
corticosteroids was not associated with low birth weight or foetal
growth restriction (RR 1.08, 95% CI 0.86 to 1.36, 4 studies, n =
59,419; Analysis 1.11). We rated the quality of evidence as very
low, given that the default level of the quality of the evidence for
observational studies is low, and we downgraded the evidence one
further level due to imprecision in these results.
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Preterm delivery
A total of 4 cohort studies assessed preterm delivery (Chi 2011a;
Chi 2013;Mahé 2007;Mygind 2002), and none found significant
differences in the risk for preterm delivery between the exposed
and unexposed women (pooled RR 0.93, 95% CI 0.81 to 1.08,
4 studies, n = 59,419; Analysis 1.12). The quality of the evidence
was assessed as low.
Secondary outcomes
Foetal death
A total of four cohort studies assessed foetal death (Chi 2011a; Chi
2013; Mahé 2007; Mygind 2002), but none found any increased
risk among women who received topical corticosteroids during
pregnancy (pooled RR 1.02, 95% CI 0.60 to 1.73, 4 studies, n =
63,885; Analysis 1.13). The quality of the evidence was assessed
as very low, given that the default level of quality for observational
studies is low and we downgraded one further level due to incon-
sistency in the results (I2 = 60%). The direction of effects also
varies, and imprecision is present in that the confidence intervals
are very wide.
Mild congenital abnormality
As stated in the primary outcomes for the children, due to the lack
of studies reporting major and minor congenital abnormalities
separately, we grouped the two outcomes together and reported as
’congenital abnormality’ in the primary outcomes.
Low Apgar score
Only two cohort studies provided data relevant to this outcome.
Mahé 2007 found no children with a low Apgar score frommoth-
ers who had used very potent topical corticosteroids or from those
who did not. Chi 2013 found no significant differences in low
Apgar score between women who received and did not receive
topical corticosteroids during pregnancy (RR 0.84, 95% CI 0.54
to 1.31, 1 study, n = 9220; Analysis 1.14). We rated the quality of
the evidence as low.
Stratified analysis by corticosteroid potency
Primary outcomes (in children)
Congenital abnormality
The stratified analysis of theMygind 2002 andMahé 2007 cohort
studies (Analysis 2.1) showed that when compared with women
who did not receive topical corticosteroids, there were no signifi-
cant differences in the risk for congenital abnormality in those who
received mild or moderate topical corticosteroids (adjusted RR
0.93, 95% CI 0.23 to 3.80, n > 9263 (theMygind 2002 study did
not report the respective number of women who received mild or
moderate and potent or very potent topical corticosteroids)) and
those who received potent or very potent topical corticosteroids
(RR 0.56, 95% CI 0.14 to 2.28, n > 9342). The quality of the
evidence was rated as low. We found no significant differences for
tests between the subgroups (P = 0.62).
A stratified analysis of cohort studies (Analysis 2.2) found no as-
sociations between orofacial cleft and maternal exposure to any
potency of topical corticosteroids in the first 12 gestational weeks.
There were no significant differences for tests between the sub-
groups (P = 0.49). For the outcome of orofacial cleft, we rated the
quality of the evidence as low.
Birth weight
The stratified analysis of cohort studies found no significantly
increased risk for low birth weight in women who receivedmild or
moderate topical corticosteroids when compared with those who
did not receive topical corticosteroids (pooled RR 0.90, 95% CI
0.74 to 1.09, 3 studies, n > 55,713 (the Mygind 2002 study did
not report the respective number of women who received mild
or moderate and potent or very potent topical corticosteroids);
Analysis 2.3). For this outcomewe rated the quality of the evidence
as low. However, there were significant differences between the
subgroups (P = 0.04).
We show the stratified analysis for potent to very potent topical
corticosteroids in Analysis 2.3. Although the meta-analysis based
on study-level data did not reach statistical significance (pooled
RR 1.58, 95% CI 0.96 to 2.58, 4 studies, n > 47,651 (study sub-
ject number not fully reported in the Mygind 2002 study)), the
results from individual studies indicated an increased risk of low
birth weight in women who received potent or very potent topical
corticosteroids. Mygind 2002 did not find an increased risk for
low birth weight in women who received potent or very potent
topical corticosteroids (adjusted RR 1.23, 95% CI 0.45 to 3.37, n
> 9263), but the original researchers observed a trend indicating a
dose-response relationship between low birth weight and topical
corticosteroids. Mahé 2007 and Chi 2011a demonstrated a signif-
icantly increased risk for lowbirth weight amongwomenwhoused
potent or very potent topical corticosteroids duringpregnancy (RR
2.84, 95% CI 1.07 to 7.54, n = 79) and (RR 2.08, 95% CI 1.40
to 3.10, n = 30,372), respectively. Chi 2011a reported a ’number
needed to treat for an additional harmful outcome (NNTH)’ of
168. When not considering the quantity of corticosteroids, Chi
2013 did not identify a significantly increased risk for low birth
weight among women who used potent or very potent topical cor-
ticosteroids during pregnancy (adjusted RR 1.04, 95% CI 0.73 to
1.47). However, an exploratory analysis reported in the Chi 2013
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study found an increased risk for those who received a cumulative
dose of more than 300 g of potent or very potent topical corticos-
teroids during the entire pregnancy (adjusted RR 7.74, 95% CI
1.49 to 40.11, n = 7937).
Preterm delivery
The stratified analysis of cohort studies showed that when com-
pared with women who did not receive topical corticosteroids,
there were no significant differences in the risk for preterm deliv-
ery in those who received mild or moderate versus potent or very
potent topical corticosteroids (adjusted RR being 0.88, 95% CI
0.75 to 1.03, n > 55,713 (the Mygind 2002 study did not report
the respective number of women who received mild or moderate
and potent or very potent topical corticosteroids) and RR 1.05,
95% CI 0.85 to 1.31, n > 47,651, respectively) (Analysis 2.4). We
rated the quality of the evidence as low. There were no significant
differences between the subgroups (P = 0.19).
Secondary outcomes
Foetal death
The stratified analysis of the cohort studies according to corti-
costeroid potency (Analysis 2.5) found no increased risk of foetal
death and a seemingly protective effect for mild to moderate topi-
cal corticosteroids on foetal death (pooled RR 0.70, 95% CI 0.64
to 0.77, 2 studies, n = 48,749; low quality evidence; Chi 2011a;
Chi 2013) and for potent to very potent topical corticosteroids
(pooled RR 1.14, 95% CI 0.69 to 1.88, 3 studies, n = 37,086; low
quality evidence; Chi 2011a; Chi 2013; Mahé 2007). There were
no significant differences between the subgroups (P = 0.06).
Low Apgar score
The stratified analysis of the cohort studies according to corticos-
teroid potency (Analysis 2.6) did not find an increase in low Ap-
gar score in women who received mild or moderate topical cor-
ticosteroids (RR 0.73, 95% CI 0.45 to 1.20; 1 study n = 8756;
low quality evidence; Chi 2013). This was also the case in those
who received potent or very potent topical corticosteroids during
pregnancy (RR 1.03, 95% CI 0.52 to 2.03, 2 studies, n = 7514;
low quality evidence; Chi 2013; Mahé 2007). There were no dif-
ferences between the subgroups (P = 0.43).
Sensitivity analysis after excluding poor-quality studies
Whenwe ran sensitivity analyses after excluding poor quality stud-
ies (i.e., Czeizel 1997 and Edwards 2003, which had a high risk
of bias due to high non-response rate), we found no significant
associations between maternal exposure to topical corticosteroids
and orofacial cleft (OR 0.98, 95% CI 0.53 to 1.82, 6 studies, n =
604,300; Analysis 3.1), its two categories: cleft lip with or with-
out cleft palate (OR 1.20, 95% CI 0.73 to 1.97, 6 studies, n =
602,620; Analysis 3.2), or cleft palate alone (OR 0.84, 95% CI
0.37 to 1.93, 6 studies, n = 601,082; Analysis 3.3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Mild to moderate topical corticosteroids versus no topical corticosteroids for pregnant women
Participants or population: pregnant women
Settings: population-based
Intervention: mild or moderate topical corticosteroids
Comparison: no topical corticosteroids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Unexposed
group (in cohort study)
/control group (in case-
control study)
Exposed group (in co-
hort study)/case group
(in case-control study)
Congenital abnormality Not reported Not reported RR 0.93, 95% CI 0.23 to
3.80
>9263 (1 cohort study) ++OOa
low
-
Orofacial cleft 0.10% to 0.16% 0.13% to 0.14% RR 0.95, 95% CI 0.40 to
2.28
38,446 (2 cohort studies) ++OOa
low
-
Low birth weight 0.55% to 4.80% 0.50% to 4.53% RR 0.90, 95% CI 0.74 to
1.09
>55,713 (3 cohort stud-
ies)
++OOa
low
1 study did not report the
number of women who
receivedmild ormoderate
topical corticosteroids
Preterm delivery 0.76% to 2.32% 0.75% to 2.19% RR 0.88, 95% CI 0.75 to
1.03
>55,713 (3 cohort stud-
ies)
++OOa
low
1 study did not report the
number of women who
receivedmild ormoderate
topical corticosteroids
Foetal death 0.47% to 9.27% 0.37% to 6.46% RR 0.70, 95% CI 0.64 to
0.77
48,749 (2 cohort studies) ++OOa
low
-
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Low Apgar score 1.30% 0.95% RR 0.73, 95% CI 0.45 to
1.20
8756 (2 cohort studies) ++OOa
low
-
*The basis for the assumed risk is the prevalence of the outcome in the control group. The corresponding risk is based on the assumed risk in the comparison group and the relative effect
of the intervention (and its 95% CI).
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate
RR: risk ratio; OR: odds ratio; CI: Confidence interval.
a The default level of the quality of the evidence for observational studies is low.
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Potent or very potent topical corticosteroids compared with no topical corticosteroids for pregnant women
Participants or population: pregnant women
Settings: ranging from a single hospital to a population-based database
Intervention: potent or very potent topical corticosteroids
Comparison: no topical corticosteroids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Unexposed
group (in cohort study)
/control group (in case-
control study)
Exposed group (in co-
hort study)/case group
(in case-control study)
Congenital abnormality 0% to 3.6% 0% to unknown RR 0.56, 95% CI 0.14 to
2.28
>9342 (2 cohort studies) ++OOa
low
1 study did not report the
number of women who
received potent or very
potent topical corticos-
teroids
Orofacial cleft 0.10% to 0.16% 0.21% to 0.36% RR 1.50, 95% CI 0.59 to
3.82
36,348 (2 cohort studies) ++OOa
low
-
Low birth weight 0.55% to 10.71% 1.21% to 30.43% RR 1.58, 95% CI 0.96 to
2.58
>47,651 (4 cohort stud-
ies)
++OOa
low
1 study did not report the
number of women who
received potent or very
potent topical corticos-
teroids
Preterm delivery 0% 6.4% 0.97% to 3.57% RR 1.05, 95% CI 0.85 to
1.31
>47,651 (4 cohort stud-
ies)
++OOa
low
-
Foetal death 0% to 9.27% 0% to 8.76% RR 1.14, 95% CI 0.69 to
1.88
37,086 (3 cohort studies) ++OOa
low
-
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Low Apgar score 0% to 1.30% 0% to 1.34% RR 1.03, 95% CI 0.52 to
2.03
7514 (2 cohort studies) ++OOa
low
-
*The basis for the assumed risk is the prevalence of the outcome in the control group. The corresponding risk is based on the assumed risk in the comparison group and the relative effect
of the intervention (and its 95% CI).
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate
RR: risk ratio; OR: odds ratio; CI: Confidence interval.
aThe default level of the quality of the evidence for observational studies is low.
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D I S C U S S I O N
Summary of main results
After including seven new studies for this update, the overall qual-
ity of evidence from the included observational studies was still
low (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3). We downgraded the evi-
dence because we detected wide confidence interval values (impre-
cision) and clinical and statistical heterogeneity (inconsistency).
Lower quality evidence resulted in lower confidence in the esti-
mate of effect for those outcomes. Most of the studies did not find
significant associations between maternal use of topical corticos-
teroids and pregnancy outcomes, including mode of delivery, con-
genital abnormality (including orofacial cleft), preterm delivery,
and foetal death (Carmichael 2007; Carmichael 2009; Chi 2011a;
Chi 2013; Czeizel 1997; Källén 2003; Mahé 2007; Mygind 2002;
Pradat 2003; Skuladottir 2014a; Skuladottir 2014b; Skuladottir
2014c). Although one small case-control study, Edwards 2003,
identified a significant association between topical corticosteroids
and orofacial cleft, the study subjects were from a single hospi-
tal, and the statistical power was very low because of the small
sample size (48 cases and 58 controls). Furthermore, the response
rate for the case and control groups was only 25.3% and 14.2%,
respectively. Hviid 2011 compared use of various forms of corti-
costeroids during pregnancy in those with and without orofacial
cleft and found a link between maternal exposure to topical corti-
costeroids and cleft lip with or without cleft palate. However, the
study authors found no dose-response nor potency-response rela-
tionship and concluded it was a spurious finding resulting from
multiple comparisons. There was limited data from two case-con-
trol studies suggesting an association between fewer hypospadias
and maternal use of topical corticosteroids, but this did not reach
statistical significance (Czeizel 1997; Carmichael 2009).
We were unable to conduct our originally planned subgroups of
maternal skin conditions (polymorphic eruption of pregnancy,
pemphigoid gestationis, etc.) and maternal ages because the data
were unavailable from the investigators of studies included in this
review. We elected to conduct a post hoc analysis based on steroid
potency, as recent evidence suggests that potent topical corticos-
teroids are associated with low birth weight. The stratified meta-
analyses according to corticosteroid potency found no significant
associations between low birth weight with maternal exposure to
topical corticosteroids of any potency. However, the data from in-
dividual studies proposed a relationship between low birth weight
and the potency and dose of topical corticosteroids as follows: two
cohort studies found a significant association between maternal
exposure to potent or very potent topical corticosteroids and low
birth weight (Chi 2011a; Mahé 2007). In another cohort study,
an exploratory analysis found an increased risk of low birth weight
when the cumulative dose of potent or very potent topical corti-
costeroids exceeded 300 g during the entire pregnancy (Chi 2013).
The post hoc stratified analysis by steroid potency (from two stud-
ies: Chi 2011a and Chi 2013), found that mild or moderate top-
ical corticosteroids had a seemingly protective effect of on foetal
death (RR 0.70, 95% CI 0.64 to 0.77; Analysis 2.5). However,
this finding was not supported by a dose-response relationship.
Overall completeness and applicability of
evidence
The body of evidence has substantially increased since our pre-
vious review, with the contribution from seven new studies. Due
to the restriction of study design, the only outcomes measured
in all nine case-control studies were congenital abnormality, oro-
facial cleft, and hypospadias (Czeizel 1997; Carmichael 2007;
Carmichael 2009; Edwards 2003; Källén 2003; Pradat 2003;
Skuladottir 2014a; Skuladottir 2014b; Skuladottir 2014c). Hviid
2011 was a cohort study but only assessed orofacial cleft. Only in
the other four cohort studies were other pregnancy outcomes (such
as birth weight and preterm delivery) investigated (Chi 2011a;
Chi 2013; Mahé 2007; Mygind 2002).
When assessing the teratogenic risk of topical corticosteroids, the
definition of ’case’ varied substantially among the case-control
studies. The Hungarian study, Czeizel 1997, defined cases as chil-
dren having an isolated congenital abnormality or unidentified
multiple congenital abnormalities and excluded those with some
mild congenital abnormalities, minor anomalies, or congenital ab-
normality syndromes of known origin. We performed stratified
analyses on fourteen congenital abnormality groups. The other
seven case-control studies restricted cases to children having an
orofacial cleft (Carmichael 2007; Edwards 2003; Källén 2003;
Pradat 2003; Skuladottir 2014a; Skuladottir 2014b; Skuladottir
2014c).
A total of 10observational studies analysed cleft lipwith orwithout
cleft palate and cleft palate alone separately (Carmichael 2007;
Chi 2011a; Chi 2013; Czeizel 1997; Edwards 2003; Hviid 2011;
Pradat 2003; Skuladottir 2014a; Skuladottir 2014b; Skuladottir
2014c).
Orofacial cleft is classified into syndromic and non-syndromic
clefts according to whether associated congenital abnormalities are
present or not. Syndromic orofacial cleft occurs due to idiopathic,
inherited, or chromosomal defects and presents with associated
congenital abnormalities. Non-syndromic cleft is believed to be
the result of multifactorial environmental and genetic factors, with
a low risk of familial occurrence (Edwards 2003). It is more likely
to be subject to the influence of environmental insults, so many
teratologic studies only included cases of non-syndromic cleft.
Edwards 2003 included only children with non-syndromic orofa-
cial cleft. Carmichael 2007, Hviid 2011, and Skuladottir 2014a
only included non-syndromic orofacial cleft and further excluded
those with a recognised or strongly suspected single-gene disorder
or chromosomal abnormality. On the other hand, Källén 2003
and Skuladottir 2014c did not exclude children with a syndrome
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diagnosis. The original researcher of the Källén 2003 study argued
that those with a syndrome diagnosis only occupied 5% in his
series, that the quality of diagnosing clinical syndromes was oc-
casionally doubtful, and that drug exposure may modify the phe-
notypic expression. Pradat 2003 also included in the case group
children with multiple congenital abnormalities, syndromes, and
even known causes like chromosomal defect.
In a clinical setting, it is sometimes difficult to distinguish non-
syndromic cleft from syndromic cleft. Orofacial cleft without asso-
ciated malformations may be merely an incomplete manifestation
of the syndromic cleft (Wong 2004). The difficulty in precisely
identifying cases that are vulnerable to environmental influences
can compromise the accuracy of risk assessment. An analysis on
all clefts followed by a sensitivity test excluding cases of syndromic
cleft, as performed in the Carmichael 2007 and Skuladottir 2014b
studies, can resolve this problem. The results of the sensitivity test
excluding syndromic cleft were very similar to the results without
the exclusion.
The selection and definition of controls also varied among the
case-control studies. In the Czeizel 1997 study, the controls
were healthy newborns selected from the national birth register
matched for gender, birth week, and district of parents’ residence.
Källén 2003 study healthy controls from a national birth regis-
ter. Carmichael 2007, Carmichael 2009, Hviid 2011, Skuladottir
2014a, Skuladottir 2014b, and Skuladottir 2014c randomly se-
lected healthy controls from birth registries, birth certificates, or
from birth hospitals. Edwards 2003 also used healthy controls
matched by birth date, but the source was limited to the same hos-
pital. On the other hand, Pradat 2003 merely enrolled malformed
infants with a history of maternal first trimester drug exposure and
used ’sick controls’, i.e., infants with other congenital anomalies
from the same database, for comparison. The influence on the
direction of effects on risk assessment is unclear. The external va-
lidity is highly dependent on the robustness of the register.
The selection of study subjects in the cohort studies also dif-
fered. Mygind 2002 restricted their study subjects to primiparous
women. Mahé 2007 only included women who used potent top-
ical corticosteroids for skin lightening during pregnancy and ex-
cluded women receiving topical corticosteroids for a medical rea-
son. These restrictions limit the external validity of the two studies.
On the other hand, Chi 2011a and Chi 2013 included all preg-
nant women aged 15 to 44 years except for those with multifoetal
pregnancy or pregnancy following assisted reproduction.
Quality of the evidence
We did not find any randomised controlled trials (RCTs) relevant
to this review. The most likely reason for the absence of relevant
RCTs stems from ethical concerns that result in the exclusion of
pregnant women from clinical trials unless the objective is to in-
vestigate a pregnancy-related condition (Meadows 2001).We only
identified 14 relevant observational studies, including 5 cohort
and 9 case-control studies, with a total of 1,601,515 study sub-
jects (Carmichael 2007; Carmichael 2009; Chi 2011a; Chi 2013;
Czeizel 1997; Edwards 2003; Hviid 2011; Källén 2003; Pradat
2003; Mahé 2007; Mygind 2002; Skuladottir 2014a;Skuladottir
2014b; Skuladottir 2014c).
We used the Grades of Recommendation, Assessment, Develop-
ment and Evaluation (GRADE) system to evaluate the quality
of the evidence for outcomes reported in this review (Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3). Because only observational studies were
available, the body of evidence was assigned by default as ’low qual-
ity’ according to the GRADE system (Higgins 2011). Regarding
the outcome ’foetal death’ in Summary of findings for the main
comparison, we further downgraded the quality of evidence due
to inconsistency. For the outcome of low birth weight, we also
downgraded further to ’very low quality’ on the basis of impreci-
sion. The confidence intervals of the risk ratio (0.86 to 1.36) were
quite narrow; however, they were wide for each study, and while
the variations in the absolute data may reflect the variations in the
baseline risk of different studies, we are still very uncertain about
the effect estimate.
In the Mygind 2002 study, the records of congenital abnormality
in the register were not entirely accurate. Among the five regis-
tered congenital abnormality cases in the exposed group, a review
of their hospital records revealed that two babies actually did not
have any congenital abnormalities. All of the remaining three cor-
rectly recorded cases belonged to malformations of the foot (club
foot, flat foot, and metatarsus varus) instead of orofacial cleft as
suggested by animal studies.
The measurement of exposure varied considerably among the in-
cluded studies. Six case-control studies retrospectively measured
exposure (Carmichael 2007; Carmichael 2009; Edwards 2003;
Pradat 2003; Skuladottir 2014a; Skuladottir 2014b). Recall bias
may be introduced especially when the outcomes were already
known (Altman 1991). The information of exposure may be more
detailed, and the timing of exposure may be misleading in the
case group since the mothers tend to attribute the adverse out-
come to an explainable cause. On the other hand, the exposure in
the controls is often underreported. Furthermore, as the length of
time after exposure increases, detailed memory of exposure may
be compromised, amplifying the risk of recall bias.
The Källén 2003 and Skuladottir 2014c studies prospectively col-
lected data of first-trimester drug use at antenatal visits. Prospec-
tive measurement can reduce recall bias, and well-trained research
staff can make vigorous attempts to acquire the details of women’s
adherence, dosage, potency, application, and duration of topical
corticosteroids use from co-operative study subjects. The Czeizel
1997 study used a variety of prospective and retrospective infor-
mation sources, encompassing a prenatal log book, questionnaire,
and interview, to assess drug exposure. The use of regional district
nurse visits increased the response rate in the case group by 10%.
This mechanism might have incurred further differences between
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the two groups. The original researcher did not perform a sub-
group analysis; thus, the direction of its influence on pregnancy
outcomes is not clear.
Chi 2011a, Chi 2013, Hviid 2011, and Mygind 2002 used link-
age to the prescription database to provide the exposure data. Pre-
scription databases have the advantage of providing details of ex-
posure, such as the constituents and dosage of medicines, and the
data aremore accurate than study subjects’ memory.However, pre-
scription databases cannot offer data on study subjects’ adherence
and whether study subjects used over-the-counter topical corti-
costeroids, topical corticosteroids from previous prescriptions, or
even prescriptions from their relatives or friends.
The most crucial period for foetal organogenesis is from the 4
th to 10th week of gestation. Teratogen exposure during this pe-
riodmay cause major malformations. Foetal maturation and func-
tional development continue after the 11th week, and certain or-
gans remain vulnerable. Teratogen exposure may cause functional
defects and minor malformations (Cunningham 2005). The crit-
ical period for the fusion of the lip and palate (from the primary
and second palates, respectively) is from the 5th to 12th gesta-
tional week (Arosarena 2007). The examined timing of exposure
differed among the studies on congenital abnormality or orofa-
cial cleft. Most studies examined exposure in the first trimester of
gestation (Edwards 2003; Källén 2003; Pradat 2003) or the first
three months of gestation (Skuladottir 2014b). Mygind 2002 ex-
amined exposure from 30 days before conception until the end of
the first trimester of gestation. Chi 2011a considered the possi-
bility of prolonged use after obtaining topical corticosteroids and
examined exposure from 85 days before conception until the 12
th gestational week in the primary analysis and then conducted a
sensitivity analysis by examining exposure from the last menstrual
period to the 12th gestational week. Chi 2013 examined expo-
sure from the last menstrual period to the 12th gestational week.
Carmichael 2007 and Skuladottir 2014a examined exposure from
4weeks before conception to 12 weeks after conception. Similarly,
the Czeizel 1997 study only regarded exposure in the second and
third months of gestation as crucial. Skuladottir 2014c assessed
drug exposure from six months before pregnancy to the first 15
weeks of pregnancy.
Controlling for potential confounders is essential for observa-
tional studies, and most of our included studies performed this
(Carmichael 2007; Carmichael 2009; Chi 2011a; Chi 2013;
Czeizel 1997; Edwards 2003; Hviid 2011; Källén 2003; Mygind
2002; Skuladottir 2014a; Skuladottir 2014b; Skuladottir 2014c).
The most common confounder controlled was smoking (in nine
studies), followed by maternal age (in eight studies) and birth
order (in four studies). Pradat 2003 controlled for no potential
confounders but used the Mantel-Haenszel method to adjust for
the register that provided the cases. Mahé 2007 did not control
for potential confounders in their analysis, although there were
no significant differences between women who used very potent
corticosteroids and those who did not in terms of potential con-
founders such as socioeconomic and education levels, age, and
parity.
Maternal conditions indicated for topical corticosteroidsmay have
a direct impact on pregnancy outcomes. For example, an increased
risk for foetal growth restriction occurs in women with pem-
phigoid gestationis, whereas adverse pregnancy outcomes, includ-
ing pretermdelivery, intrapartal foetal distress, and stillbirths, hap-
pen more frequently in women with intrahepatic cholestasis of
pregnancy (Ambros-Rudolph 2006). On the other hand, there is
no evidence indicating that eczema affects pregnancy outcomes
(Weatherhead 2007). Only the Chi 2011a study controlled for
the confounding by indication. Czeizel 1997 prescribed corticos-
teroid ointments for allergic dermatoses, such as urticaria and
eczema, in both the case and control groups. The indications
in all nine exposed cases were dermatitis or eczema in the Aus-
tralian study (Edwards 2003). All the exposed women in the Sene-
galese study used topical corticosteroids for skin-lightening (Mahé
2007). Thus, the maternal indications for topical corticosteroids
in these studies were unlikely to affect pregnancy outcomes.Mean-
while, the indications for topical corticosteroids in pregnancy were
unavailable in the other studies (Carmichael 2007; Chi 2013;
Hviid 2011; Källén 2003;Mygind 2002; Pradat 2003; Skuladottir
2014a; Skuladottir 2014b; Skuladottir 2014c). In Carmichael
2007, a stratified analysis by indication was not undertaken be-
cause of a lack of relevant records in most women.
Concurrent use of other medications or nutritional supplements
in pregnancy may also affect pregnancy outcomes and thus should
be considered. For example, isotretinoin is a potent teratogen,
while folic acid reduces the risk of neural tube defects and other
congenital abnormalities (Briggs 2008). Four studies considered
the concurrent use of other medications (Carmichael 2007; Chi
2011a; Chi 2013; Czeizel 1997; Edwards 2003; Källén 2003).
Two cohort studies (Chi 2011a; Chi 2013) adjusted for maternal
exposure to the US Food and Drug Administration (FDA) preg-
nancy risk category D or Xmedicines in analyses. Czeizel 1997 did
not find any significant difference in the frequency of concurrent
use of 10 medications. Two case-control studies compared mater-
nal intake of folic acid in early pregnancy and did not find sig-
nificant differences (Carmichael 2007; Edwards 2003). Another
case-control study, Källén 2003, compared the frequency of use of
30 medications in the first trimester of gestation and also identi-
fied a significant association of orofacial cleft with naproxen. The
Hviid 2011 study compared maternal exposure with five specified
categories of medicines and found no differences between the ex-
posed and control groups. By contrast, the other five studies did
not consider concurrent use of other medications, and thus did
not control for confounding (Mahé 2007; Mygind 2002; Pradat
2003; Skuladottir 2014b; Skuladottir 2014c).
Potential biases in the review process
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Wedid not deliberately examine all trials on topical corticosteroids
to find out if they contained any pregnant women. However, we
contacted 11 pharmaceutical companies that have introduced an
original topical corticosteroid product to provide relevant stud-
ies and did not obtain any relevant data. Furthermore, pregnant
women are routinely excluded from clinical trials unless the objec-
tive is to assess a drug’s efficacy on a pregnancy-related condition.
Thus, it is unlikely that we have missed relevant studies for this
review.
Given the high degree of bias found in non-randomised studies,
which are the sole source of evidence, we expected some degree
of statistical heterogeneity and only applied meta-analysis tech-
niques as appropriate. That is, we used the I2 statistic to examine
the statistical heterogeneity, and when levels of statistical hetero-
geneity were high, we elected to pool the data only where there
was reasonable clinical homogeneity to provide further evidence;
however, we accept that this decision may limit the reliability and
applicability of the findings.
Agreements and disagreements with other
studies or reviews
We did not find specific reviews on the safety of topical corticos-
teroids in pregnancy but found three narrative reviews on derma-
tological treatments for pregnant women (Hale 2002; Leachman
2006; Zip 2006). None of these were systematic reviews, and none
included any of the seven relevant studies identified in our previ-
ous review. The three reviews only quoted a case report of foetal
growth restriction following maternal use of 40 mg/d of triamci-
nolone cream (Katz 1990), and they pointed to topical corticos-
teroids as having the FDA pregnancy risk class C. Thus, the data
included in previous reviews were incomplete, and their conclu-
sions were accordingly limited. Another European evidence-based
guideline on topical corticosteroids in pregnancy, Chi 2011b, was
based on data from the previous version of this review and two
studies included in this updated review (Chi 2009; Chi 2011a;
Hviid 2011).
Although the meta-analyses in this review did not reach statistical
significance for the outcome of low birth weight, the results from
individual studies indicated a potential for increased risk of low
birth weight in women who received potent or very potent topical
corticosteroids. In this review, we did not address dose-response
relationships, but other studies have explored whether there may
be a dose-response relationship between low birth weight and top-
ical corticosteroids. Mygind 2002 observed a trend indicating a
dose-response relationship between low birth weight and topical
corticosteroids. Chi 2011a found a significant dose-response re-
lationship between the quantity of potent or very potent topical
corticosteroids and low birth weight (P = 0.025). Chi 2013 con-
ducted an exploratory analysis on the associations of the cumu-
lative dosage (in the entire pregnancy) of potent or very potent
topical corticosteroids with low birth weight. That study found an
increased risk for those who receivedmore than 300 g of potent or
very potent topical corticosteroids during pregnancy (adjusted RR
7.74, 95% CI 1.49 to 40.11, n = 7937). The available evidence
for maternal use of potent or very potent topical corticosteroids
may therefore suggest that such usage, especially in large quanti-
ties, could be associated with low birth weight, but more studies
are needed to confirm this.
The stratified analysis in this review of foetal death by steroid po-
tency found a possible protective effect of mild to moderate topi-
cal corticosteroids. However, this finding was not supported by a
dose-response relationship in Chi 2011a (for both mild to mod-
erate and potent to very potent topical corticosteroids). It should
not be inferred that mild to moderate topical corticosteroids may
prevent foetal death in pregnant women with or without skin dis-
orders. Further explorations of whether a dose-response relation-
ship exists were outside the scope of this review, so it is difficult
to draw any firm conclusions, but further investigation may be
warranted to determine whether nuances such as steroid potency
and cumulative dose have differential effects on outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current evidence shows a small risk of low birth weight in
pregnant women who receive potent or very potent topical corti-
costeroids, especially in large quantities. On the other hand, ma-
ternal use of mild or moderate topical corticosteroids is not related
to low birth weight. The available evidence does not support a
causal relationship between maternal use of topical corticosteroids
(of any potency) and other pregnancy outcomes, including mode
of delivery, congenital abnormality, preterm delivery, foetal death,
and low Apgar score.
Implications for research
Most of the previous studies purely assessed the risk for congenital
abnormality or orofacial cleft. Only four studies had data on other
pregnancy outcomes. More data on outcomes, such as preterm
birth, foetal death,mode of delivery, birth weight, lowApgar score,
or a selected core set of outcomes, as suggested by Devane 2007,
should be collected and analysed in future research by adopting a
cohort study design.
In this updated version of the review, we did not find a significantly
increased risk of lowbirth weight withmaternal exposure to potent
or very potent topical corticosteroids in study-level meta-analysis.
However, there is a probable association between low birth weight,
steroid potency and potentially the cumulative dosage of topical
corticosteroids throughout the pregnancy, and this warrants fur-
ther investigation. The finding of a possible protective effect of
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mild or moderate topical corticosteroids on foetal death could also
be examined.
Therefore, the effects of potency anddose of topical corticosteroids
as well as the duration, site, and extent of application should be
assessed in future research. The confounding from maternal indi-
cation for topical corticosteroids in pregnancy outcomes should
be considered in order to mitigate its effect on the results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carmichael 2007
Methods Case-control
Participants Inclusion: 1141 infants with cleft lip with or without cleft palate, 628 infants with cleft
palate alone
Exclusion: recognised or strongly suspected single-gene disorders or chromosomal ab-
normalities
Controls: 4143 control infants without major congenital malformations randomly se-
lected from birth certificates or birth hospitals
Interventions Topical corticosteroids
Outcomes Cleft lip with or without cleft palate, cleft palate alone
Funding source Centers for Disease Control and Prevention
Notes Country: USA
Setting: population-based (National Birth Defects Prevention Study)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
Was the case definition adequate? Low risk Cases of orofacial cleft received an additional review by one
clinical geneticist to ensure that standard eligibility criteria were
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Carmichael 2007 (Continued)
met
Representativeness of the cases Low risk Idenitifed from birth defect surveillance systems in 8 US states
Selection of the controls Low risk Controls were randomly selected from birth certificates or birth
hospitals
Definition of the controls Low risk Infants without major congenital malformations
Comparability of cases and controls on the
basis of the design or analysis
Low risk Controlled for potential confounders including maternal race/
ethnicity, education, intake of folic acid-containing supplements
or smoking during the month before or the first 3 months of
pregnancy, and study centre
Ascertainment of exposure Unclear risk Interview not blinded to case/control status
Same method of ascertainment for cases
and controls
Low risk Same method of ascertainment used in both groups
Non-response rate Unclear risk NA
Carmichael 2009
Methods Case-control
Participants Inclusion: 1165 cases of second- or third-degree hypospadias, that is, with the urethral
opening at the penile shaft, scrotum, or perineum
Exclusion: cases described as chordee alone, mild hypospadias (i.e., first-degree, coronal,
or glandular), hypospadias not otherwise specified, epispadias, or ambiguous genitalia
without further description; infants with recognised single gene disorders, female kary-
otypes, or chromosomal abnormalities also excluded
Controls: 3000 non-malformed male controls
Interventions Topical corticosteroids
Outcomes Hypospadias
Funding source Centers for Disease Control and Prevention
Notes Country: USA
Setting: population-based (National BirthDefects Prevention Study) fromOctober 1997
to December 2004
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
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Carmichael 2009 (Continued)
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
Was the case definition adequate? Low risk Quote: “Each case received a final review by a single clinical
geneticist (R.O.) to ensure that cases from each study center met
standard eligibility criteria. This geneticist also classified each
case as isolated, if therewas no concurrentmajor anomaly or only
a minor anomaly (e.g., sacral/pilonidal dimple), or multiple, if
there was at least 1 unrelated accompanying major anomaly and
in another organ system”
Representativeness of the cases Low risk Identified from birth defect surveillance systems in 10 US states
Selection of the controls Low risk Quote: “Each state randomly selected approximately 100 non-
malformed liveborn controls per study year from birth certifi-
cates”
Definition of the controls Low risk Non-malformed male infants
Comparability of cases and controls on the
basis of the design or analysis
Low risk Controlled for potential confounders including maternal edu-
cation, race/ethnicity, age, number of previous live births, folic
acid-containing supplement intake, smoking, body mass index,
subfertility, and study site
Ascertainment of exposure Unclear risk Quote: “Maternal interviews were conducted using a standard-
ized, computer-based telephone questionnaire in English or
Spanish, no earlier than 6 weeks and no later than 24 months
after the infant’s estimated date of delivery”
Same method of ascertainment for cases
and controls
Unclear risk Quote: “The mean time from delivery to interview was 13.2
months in the mothers of cases and 8.9 months in the mothers
of controls”
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Carmichael 2009 (Continued)
Non-response rate Unclear risk The non-response rate in the case group was 23%. The non-
response rate in the mothers of all controls in the congenital
abnormality registry was 25%, but the exact rate in the mothers
of male-only controls was unavailable
Chi 2011a
Methods Retrospective cohort study
Participants Inclusion: 35,503 pregnant women aged 15-44 years, having registered with the practice
with up-to-standard follow-up for at least 6 months before last menstrual period, having
1 or more prescriptions for topical corticosteroids during the period from 85 days before
last menstrual period (LMP) to delivery or foetal death
Exclusion: women prescribed oral, injected, inhaled, ophthalmological, or haemor-
rhoidal corticosteroids during the same period; women with multifoetal pregnancies
Controls: 48,630 unexposed women not having prescriptions for any corticosteroid
preparations during the period from 85 days before LMP to delivery or foetal death
Interventions Topical corticosteroids prescribed during the period from 85 days before LMP to delivery
or foetal death. Exposure was defined as beginning at 85 days before LMPbecause women
may use topical corticosteroids for some time after receiving the prescriptions
Outcomes 1. Orofacial cleft and its two subtypes: cleft lip with or without cleft palate; and cleft
palate alone
2. Foetal growth restriction (diagnosed as small-for-dates, birth weight < 2500 g, or
birth weight < 10th percentile)
3. Preterm delivery (delivery before 37 completed weeks of gestation)
4. Foetal death and its two categories, miscarriage (early foetal death before 24
completed weeks of gestation) and stillbirth (late foetal death after 24 completed weeks
of gestation)
Funding source UK Medical Research Council, British Skin Foundation, John Fell Oxford University
Press Research Fund, and Chang Gung Memorial Hospital, Chiayi
Notes Country: UK
Setting: population-based (UK General Practice Research Database)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Low risk Obtained from the UK General Practices Research
Database, which has the primary care records of over 3.
5 million currently registered patients (5.5% of the UK
population); broadly representative of pregnant women in
UK population
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Chi 2011a (Continued)
Selection of the non-exposed cohort Low risk Drawn from the same source as the exposed cohort
Ascertainment of exposure Low risk Quote: “The prescription records were used to identify
the timing, potency, and dosage of topical corticosteroids
prescribed”
Demonstration that the outcome of inter-
est was not present at start of study
Low risk The outcomes of interest did not happen at the start of the
study
Comparability of cohorts on the basis of
the design or analysis
Low risk There were non-clinically significant differences between
the exposed and control cohorts in the potential co-
founders, which had been adjusted in statistical analyses
Assessment of outcome Low risk Diagnostic codes used to identify the outcomes in the clin-
ical records
Was the follow-up long enough for the out-
comes to occur?
Low risk The study subjects followed up until delivery or foetal
death
Adequacy of follow-up of the cohorts Low risk Compared to the usual reported rate of 3-7%, the inci-
dence of foetal growth restriction of 0.59% in the study
was low. “The low number of foetal growth restriction
events could lead to loss of statistical power, resulting in
underestimation of the true effect and type II error; i.e.
, a truly significant association is not detected. However,
our study has detected a significant association between
maternal exposure to potent/very potent topical corticos-
teroids and foetal growth restriction. We assumed that
missed cases would have occurred equally in the exposed
and unexposed groups. The way that data are recorded in
the GPRD makes this a reasonable assumption”
Was the case definition adequate? Unclear risk NA
Representativeness of the cases Unclear risk NA
Selection of the controls Unclear risk NA
Definition of the controls Unclear risk NA
Comparability of cases and controls on the
basis of the design or analysis
Unclear risk NA
Ascertainment of exposure Unclear risk NA
Same method of ascertainment for cases
and controls
Unclear risk NA
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Chi 2011a (Continued)
Non-response rate Unclear risk NA
Chi 2013
Methods Retrospective cohort study
Participants Inclusion: pregnant women aged 15 to 44 years who received≥ 1 dispensed prescription
(s) for topical corticosteroids during pregnancy
Exclusion: women who had received ≥ 1 dispensed prescription(s) for any other form
(systemic, injection, inhalation, or nasal) of corticosteroids during pregnancy; women
with multifoetal pregnancy or pregnancy following assisted reproduction
Controls: pregnant women aged 15 to 44 years who did not receive any dispensed
prescription for any form of corticosteroids during pregnancy
Interventions Dispensed prescriptions for topical corticosteroids during pregnancy
Outcomes 1. Orofacial cleft
2. Low birth weight
3. Preterm delivery
4. Foetal death
5. Low Apgar score (< 7 at 5 minutes)
6. Mode of delivery
Funding source Wellbeing of Women and Chang Gung Memorial Hospital, Chiayi
Notes Country: UK
Setting: population-based (UK Health Informatics Centre datasets)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Low risk Obtained from the UK Health Informatics Centre (HIC)
datasets containing anonymised longitudinal medical
records of everyone registered with the National Health
Service (NHS) Tayside in Scotland; truly representative
of average pregnant women (monofoetal pregnancies, not
IVF) receiving topical steroids
Selection of the non-exposed cohort Low risk Drawn from the same source as the exposed cohort (match-
ing for maternal age (5-year bands), as well as the calendar
year of pregnancy
Ascertainment of exposure Low risk The pharmacy records identify the timing, potency, and
dosage of topical corticosteroids dispensed from commu-
nity pharmacies
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Chi 2013 (Continued)
Demonstration that the outcome of inter-
est was not present at start of study
Low risk None of the study subjects had the outcome of interest at
the start of the study
Comparability of cohorts on the basis of
the design or analysis
Low risk Therewere significant differences between the exposed and
control cohorts only in the proportions of subjects with
asthma and receiving US FDA pregnancy risk category D
or X drugs, which had been adjusted in statistical analysis
Assessment of outcome Low risk The birth registry and diagnostic codes in the clinical
records used to identify the outcomes
Was the follow-up long enough for the out-
comes to occur?
Low risk The study subjects were followed up till delivery or foetal
death
Adequacy of follow-up of the cohorts Low risk The HIC datasets had the data on all births
Was the case definition adequate? Unclear risk NA
Representativeness of the cases Unclear risk NA
Selection of the controls Unclear risk NA
Definition of the controls Unclear risk NA
Comparability of cases and controls on the
basis of the design or analysis
Unclear risk NA
Ascertainment of exposure Unclear risk NA
Same method of ascertainment for cases
and controls
Unclear risk NA
Non-response rate Unclear risk NA
Czeizel 1997
Methods Case-control
Participants Inclusion: 20,830 cases with isolated congenital abnormalities and unidentified multiple
congenital abnormalities
Exclusion: mild congenital abnormalities, minor anomalies, and congenital abnormality
syndromes of known origin
Controls: 35,727 newborns without congenital abnormalities as controls matched to
each case (control: case = 2 to 1 until 1988, 3 to 1 thereafter) according to sex, birth
week, and district of parents’ residence from the national birth registry of the Central
Statistical Office
Interventions Topical corticosteroids used mainly for allergic dermatoses such as urticaria and eczema
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Czeizel 1997 (Continued)
Outcomes 14 congenital abnormality groups including neural tube defect, hydrocephaly, cleft lip
with or without cleft palate, posterior cleft palate, ear congenital abnormalities, cardio-
vascular congenital abnormalities, intestinal atresia/stenosis, hypospadias, undescended
testis, poly/syndactyly, limb deficiencies, clubfoot, other isolated congenital abnormali-
ties, and multiple congenital abnormalities
Funding source Not reported
Notes Country: Hungary
Setting: population-based (using the data set Hungarian Case-Control Surveillance of
Congenital Abnormalities)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
Was the case definition adequate? Low risk Identified from Hungarian Congenital Abnormality Registry
Representativeness of the cases Low risk Population-based setting
Selection of the controls Low risk Community controls
Definition of the controls Low risk No congenital abnormalities
Comparability of cases and controls on the
basis of the design or analysis
Low risk Controlled for potential confounders including maternal age,
birth order, proportion of threatened and preterm birth, mater-
nal disorders, and use of other drugs
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Czeizel 1997 (Continued)
Ascertainment of exposure Low risk Prenatal log book, questionnaire, and interview
Same method of ascertainment for cases
and controls
Low risk Same methods of ascertainment used in both groups
Non-response rate High risk The non-response rate for the case and control groups was 18%
and 35%, respectively
Edwards 2003
Methods Case-control
Participants Inclusion: 48 cases with non-syndromic cleft lip or palate
Exclusion: syndromic cleft
Controls: 58 controls selected by date of birth as close as possible to that of cases
Interventions Topical corticosteroids for dermatitis or eczema
Outcomes Cleft lip or palate
Funding source Not reported
Notes Country: Australia
Setting: a single teaching hospital
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
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Edwards 2003 (Continued)
Was the case definition adequate? Low risk All cases had been assessed by a geneticist and a paediatrician in
the cleft palate clinic
Representativeness of the cases Unclear risk Cases were recruited from the cleft palate clinic in a teaching
hospital
Selection of the controls Unclear risk Selected from the same hospital
Definition of the controls Low risk No cleft lip or palate
Comparability of cases and controls on the
basis of the design or analysis
Low risk Controlled for potential confounders including family income,
family history of cleft, maternal age, birth length, and birth order
Ascertainment of exposure Unclear risk Telephone interview not blinded to case/control status
Same method of ascertainment for cases
and controls
Low risk Same methods of ascertainment used in both groups
Non-response rate High risk The non-response rate for the case and control groups was 70%
and 85.8%, respectively
Hviid 2011
Methods Retrospective cohort study
Participants All live births in Denmark from 1 January 1996 to 30 September 2008
Interventions All corticosteroid prescriptions given to women and filled during the first trimester
(defined as the first 12 weeks after the start of pregnancy) identified from the Danish
Prescription Drug Register
Outcomes 1. Cleft lip with or without cleft palate
2. Cleft palate alone
Funding source Danish Medical Research Council and Lundbeck Foundation
Notes Country: Denmark
Setting: population-based (the Danish Medical Birth Registry)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Low risk Obtained from the Danish Medical Birth Registry which
contains information on all live births in Denmark
Selection of the non-exposed cohort Low risk Drawn from the same source as the exposed cohort
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Hviid 2011 (Continued)
Ascertainment of exposure Low risk Quote: “Information on all corticosteroid prescriptions
given to women in the cohort and filled during the period
starting four weeks before pregnancy and ending at birth
was obtained from theDanish PrescriptionDrug Register”
Demonstration that the outcome of inter-
est was not present at start of study
Low risk The outcomes of interest did not happen at the start of the
study
Comparability of cohorts on the basis of
the design or analysis
Low risk No obvious differences in the year of birth, maternal age at
start of pregnancy, maternal parity, maternal place of res-
idence and origin, maternal level of education, socioeco-
nomic status, smoking, history of orofacial clefts and birth
defects among offspring, maternal diseases, and maternal
drug use during the first trimester
Assessment of outcome Low risk Quote: “Infants with orofacial clefts (clefts) were identified
through theNationalHospitalDischargeRegister.” “Clefts
were subcategorized as cleft lip with or without cleft palate
(ICD-10 codesQ36 andQ37) and cleft palate alone (ICD-
10 code Q35). Only diagnoses made during the first year
of life were included”
Was the follow-up long enough for the out-
comes to occur?
Low risk Study subjects were followed up till delivery
Adequacy of follow-up of the cohorts Low risk The Danish Medical Birth Registry had all the data on live
births
Was the case definition adequate? Unclear risk NA
Representativeness of the cases Unclear risk NA
Selection of the controls Unclear risk NA
Definition of the controls Unclear risk NA
Comparability of cases and controls on the
basis of the design or analysis
Unclear risk NA
Ascertainment of exposure Unclear risk NA
Same method of ascertainment for cases
and controls
Unclear risk NA
Non-response rate Unclear risk NA
44Safety of topical corticosteroids in pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Källén 2003
Methods Case-control
Participants Inclusion: 1044 infants with orofacial cleft
Exclusion: chromosome anomalies
Total number of births for the study: 576,873 births
Interventions Topical corticosteroids
Outcomes Orofacial cleft
Funding source KA Wallenberg Foundation
Notes Country: Sweden
Setting: population-based (Swedish Medical Birth Registry)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
Was the case definition adequate? Low risk The case was defined as having a diagnosis of orofacial cleft (but
without a chromosome anomaly). The case group was identified
from the SwedishMedical BirthRegistry, supplementedwith the
Swedish Registry of Congenital Malformations and theHospital
Discharge Registry
Representativeness of the cases Low risk The Swedish Medical Birth Registry covers all of Sweden, al-
though 1% to 2% of deliveries are missing in the register
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Källén 2003 (Continued)
Selection of the controls Low risk The controlswere also identified from the SwedishMedical Birth
Registry
Definition of the controls Low risk No orofacial clefts
Comparability of cases and controls on the
basis of the design or analysis
Low risk Comparisons of drug use were made as Mantel-Haenszel odds
ratio stratified for year of birth, maternal age, parity, smoking
habits, and period of involuntary childlessness
Ascertainment of exposure Low risk Data on drug exposure (mainly in first trimester) were prospec-
tively collected by midwives at first antenatal care visit (usually
week 10 to 12)
Same method of ascertainment for cases
and controls
Low risk Same methods of ascertainment used in both groups
Non-response rate Unclear risk NA
Mahé 2007
Methods Prospective cohort
Participants Inclusion: 28 women, who were 6 to 9 months pregnant and lived in the administrative
district of the maternity centre, and who used potent topical corticosteroids for skin
lightening during pregnancy (including 27 women using clobetasol propionate)
Exclusion: receiving oral or topical corticosteroids treatment for a medical reason
Controls: 60 women with no use of very potent topical corticosteroids during pregnancy
(including 6 women using topical corticosteroids of other potency for skin lightening
during pregnancy)
Interventions Very potent topical corticosteroids at a mean quantity of 60 g per month
Outcomes Mode of delivery, birth weight, low birth weight, gestational age at delivery, Apgar score
Funding source Not reported
Notes Country: Senegal
Setting: single maternity centre
We requested detailed statistics from the original researchers, but they could only provide
valid data of 79 women (including 23 exposed and 56 unexposed women) for analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk Enrolled from a maternity centre every alternate day
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Mahé 2007 (Continued)
Selection of the non-exposed cohort Low risk Drawn from the same source as the exposed cohort
Ascertainment of exposure Low risk Structured interview
Demonstration that the outcome of inter-
est was not present at start of study
Low risk None of the study subjects had the outcome of interest at the
start of the study
Comparability of cohorts on the basis of
the design or analysis
Low risk No significant differences between women using very potent
corticosteroids and those who did not, in terms of potential
confounders such as socioeconomic and education levels, age,
and parity
Assessment of outcome Low risk Outcomes obtained from delivery registers
Was the follow-up long enough for the out-
comes to occur?
Low risk The study participants were followed up until delivery
Adequacy of follow-up of the cohorts Unclear risk 10 out of 99 women (10.1%) lost to follow up
Was the case definition adequate? Unclear risk NA
Representativeness of the cases Unclear risk NA
Selection of the controls Unclear risk NA
Definition of the controls Unclear risk NA
Comparability of cases and controls on the
basis of the design or analysis
Unclear risk NA
Ascertainment of exposure Unclear risk NA
Same method of ascertainment for cases
and controls
Unclear risk NA
Non-response rate Unclear risk NA
Mygind 2002
Methods Retrospective cohort
Participants Inclusion: 363 primiparous women carrying a single foetus who filled a prescription for
topical corticosteroids 30 days before conception or during pregnancy
Controls: 9263 primiparous women carrying a single foetus in the same region, receiving
no prescriptions for topical corticosteroids 30 days before conception or during preg-
nancy
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Mygind 2002 (Continued)
Interventions Having filled a prescription for topical corticosteroids 30 days before conception or
during pregnancy
Outcomes 1. Birth weight
2. Low birth weight (< 2500 g)
3. Congenital abnormality
4. Preterm delivery
5. Stillbirth
Funding source WesternDanish Research Forum forHealth Sciences, DanishMedical ResearchCouncil,
and Foundation of Hørslev
Notes Country: Denmark
Setting: local population in North Jutland (using Danish Medical Birth register)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk Restricted to primiparous women
Selection of the non-exposed cohort Low risk Drawn from the same population
Ascertainment of exposure Low risk Record linkage using the Population-Based Prescription
Database
Demonstration that the outcome of inter-
est was not present at start of study
Low risk None of the study subjects had the outcome of interest at the
start of the study
Comparability of cohorts on the basis of
the design or analysis
Low risk Controlled for potential confounders including maternal age,
gestational age, and smoking status
Assessment of outcome Unclear risk Information on congenital abnormality was obtained from the
Regional Hospital Discharge Registry. The hospital records
of children with congenital abnormality were reviewed. The
records of congenital abnormality in the register were not en-
tirely accurate. Among the 5 registered congenital abnormality
cases in the exposed group, 2 children actually did not have
any abnormalities after reviewing their hospital records. Data
on other pregnancy outcomes were obtained from the Danish
Medical Birth Registry
Was the follow-up long enough for the out-
comes to occur?
Low risk The study subjects were followed up till delivery or foetal death
Adequacy of follow-up of the cohorts Low risk Complete follow-up because the data were from the Danish
Medical Birth Registry
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Mygind 2002 (Continued)
Was the case definition adequate? Unclear risk NA
Representativeness of the cases Unclear risk NA
Selection of the controls Unclear risk NA
Definition of the controls Unclear risk NA
Comparability of cases and controls on the
basis of the design or analysis
Unclear risk NA
Ascertainment of exposure Unclear risk NA
Same method of ascertainment for cases
and controls
Unclear risk NA
Non-response rate Unclear risk NA
Pradat 2003
Methods Case-control
Participants Inclusion: 982 infants with orofacial cleft and a maternal history of first trimester drug
intake
Controls: 10,168 infants with congenital malformations other than orofacial cleft and a
history of maternal first trimester drug intake
Interventions Topical corticosteroids
Outcomes Cleft palate or lip
Funding source Not reported
Notes Country: Multinational
Setting: Multicentre database (Malformation Drug Exposure Surveillance, MADRE)
All the infants in the MADRE database had a congenital malformation and a maternal
history of first trimester drug intake
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
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Pradat 2003 (Continued)
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
Was the case definition adequate? Low risk Based on reporting to the MADRE database
Representativeness of the cases Unclear risk Only children with congenital malformations and a positive his-
tory of maternal first trimester drug exposure were reported to
theMADRE database. That is, children with congenital malfor-
mations but without a history of maternal first trimester drug
exposure were not enrolled in the database
Selection of the controls Unclear risk Hospital controls
Definition of the controls Unclear risk Children with congenital malformations other than orofacial
cleft and with a history of maternal first trimester drug intake
Comparability of cases and controls on the
basis of the design or analysis
Unclear risk Using the Mantel-Haenszel method to adjust for register only
Ascertainment of exposure Unclear risk Based on self-report
Same method of ascertainment for cases
and controls
Low risk Same methods of ascertainment used in both groups
Non-response rate Unclear risk NA
Skuladottir 2014a
Methods Case-control study
Participants Inclusion: 2372 cleft cases (1577 infants with cleft lip with or without cleft palate and
795 infants with cleft palate alone)
Exclusion: recognised or strongly suspected single-gene disorders or chromosomal ab-
normalities
Controls: 5922 controls without major congenital malformations randomly selected
from birth certificates or birth hospitals
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Skuladottir 2014a (Continued)
Interventions Topical corticosteroids
Outcomes Cleft lip with or without cleft palate, cleft palate alone
Funding source Centers for Disease Control and Prevention
Notes Country: USA
Setting: multistate population-based (National Birth Defects Prevention Study)
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
Was the case definition adequate? Low risk Cases of orofacial cleft received an additional review by 1 clinical
geneticist to ensure that standard eligibility criteria were met
Representativeness of the cases Low risk Identified from birth defect surveillance systems in 8 US states
Selection of the controls Low risk Controls were randomly selected from birth certificates or birth
hospitals
Definition of the controls Low risk Infants without major congenital malformations
Comparability of cases and controls on the
basis of the design or analysis
Low risk Controlled for potential confounders including maternal race/
ethnicity, education, intake of folic acid-containing supplements
or smoking during the month before or the first 3 months of
pregnancy, and study centre
51Safety of topical corticosteroids in pregnancy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Skuladottir 2014a (Continued)
Ascertainment of exposure Unclear risk Interview not blinded to case/control status
Same method of ascertainment for cases
and controls
Low risk Same method of ascertainment used in both groups
Non-response rate Unclear risk NA
Skuladottir 2014b
Methods Case-control study
Participants Inclusion: 573 cleft cases (377 infants with cleft lip with or without cleft palate and 196
infants with cleft palate alone)
Control group: 763 controls without major congenital malformations randomly selected
from the Medical Birth Registry of Norway
Interventions Topical corticosteroids
Outcomes Cleft lip with or without cleft palate, cleft palate alone
Funding source Western Norwegian Health Authorities
Notes Country: Norway
Setting: The only 2 specialised surgical centres for oral cleft in Norway
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
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Skuladottir 2014b (Continued)
Was the case definition adequate? Low risk The cases were infants in Norway referred for clefts surgery
Quote: “Information for cases on accompanying birth defects or
syndromes was obtained from three sources: (1) medical records
at the hospital performing corrective surgery, (2) the Medical
Birth Registry, and (3) the mothers’ questionnaire”
Representativeness of the cases Low risk Quote: “In Norway, the treatment of all babies with CLP is car-
ried out in two specialized surgical centers in Oslo and Bergen.
.. the families of all newborn infants in Norway referred for
clefts surgery were invited to participate in a case-control study...
A total of 653 infants with clefts were eligible for study, and 573
of their families (88%) agreed to participate. There were 1006
randomly selected live-born nonmalformed controls eligible for
study, and 763 of their families (76%) agreed to participate”
Selection of the controls Low risk Quote: “Controls were randomly selected from all live births
during the same period, sampling from the Medical Birth Reg-
istry of Norway”
Definition of the controls Low risk Quote: “live-born nonmalformed controls”
Comparability of cases and controls on the
basis of the design or analysis
Low risk Quote: “We adjusted for the following potential confounders:
mother’s education (six categories), work status in early preg-
nancy (yes or no), alcohol intake (total number of drinks dur-
ing the first 3 months of pregnancy; none, 1-3, 4-6, and 7 +),
smoking (none, passive only, 1-5 cigarettes/d, 6-10 cigarettes/d,
and 11 + cigarettes/d), folic acid supplementation (none, < 400
µg/d, and 400 + µg/d), dietary folates (quartiles with cutoffs at
171, 214, and 264 µg/d), multivitamin supplementation (yes
or no), and calendar year of baby’s birth”
Ascertainment of exposure Low risk Quote: “All mothers in the case-control study completed a self-
administered questionnaire after delivery covering demographic
information and a wide range of exposures during pregnancy. In
particular, mothers were asked detailed questions about their use
of prescribed and over-the-counter medications during the first,
second and third month of pregnancy.” “Information on medi-
cations was collected for only the first 3 months of pregnancy”
Same method of ascertainment for cases
and controls
Low risk Same as above
Non-response rate Unclear risk NA
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Skuladottir 2014c
Methods Although the authors claimed this study (the Norwegian Mother and Child Cohort
Study) had a cohort design, we judged it as a case-control study after examining the full
text
Participants Inclusion: 123 cases with cleft lip with or without cleft palate and 61 with cleft palate
alone identified through the Medical Birth Registry of Norway
Control group: 551 mothers randomly selected from the MoBa cohort
Interventions Topical corticosteroids
Outcomes Cleft lip with or without cleft palate, cleft palate alone
Funding source Western Norwegian Health Authorities
Notes Country: Norway
Setting: population-based
Risk of bias
Bias Authors’ judgement Support for judgement
Representativeness of the exposed cohort Unclear risk NA
Selection of the non-exposed cohort Unclear risk NA
Ascertainment of exposure Unclear risk NA
Demonstration that the outcome of inter-
est was not present at start of study
Unclear risk NA
Comparability of cohorts on the basis of
the design or analysis
Unclear risk NA
Assessment of outcome Unclear risk NA
Was the follow-up long enough for the out-
comes to occur?
Unclear risk NA
Adequacy of follow-up of the cohorts Unclear risk NA
Was the case definition adequate? Low risk Quote: “Cases within the cohort were iden-
tified by linking all cohort members with
the Medical Birth Registry, which includes
information on all defects recorded during
the newborn’s hospital stay. For oral clefts,
the sensitivity of theMedical Birth Registry
is 94% for cleft lip with or without cleft
palate and 57% for cleft palate only”
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Skuladottir 2014c (Continued)
Representativeness of the cases Low risk The cases with orofacial cleft were identi-
fied through the Medical Birth Registry of
Norway
Selection of the controls Low risk The control group was randomly selected
from the same population-based study
Definition of the controls Low risk Same as above
Comparability of cases and controls on the
basis of the design or analysis
Low risk Quote: “We adjusted for folic acid use
(400 µg/d or none), smoking (none, pas-
sive only, and active smoker), mother’s ed-
ucation (< high school and high school or
more) and alcohol consumption (none or
any)”
Ascertainment of exposure Low risk Quote: “Mothers in the cohort study were
asked to complete self-administered ques-
tionnaires at pregnancy week 15, 22, and
30.We used information from the 15-week
questionnaire, which focuses on maternal
health and use of medications 6 months
before pregnancy and during the first 15
weeks of pregnancy”
Same method of ascertainment for cases
and controls
Low risk Same as above
Non-response rate Unclear risk Representativeness of the exposed cohort
CLP: cleft lip or palate or both; FDA: Food and Drug Administration (USA); IVF: in vitro fertilisation; LMP: last menstrual period;
MoBa: Norwegian Mother & Child Cohort Study (from Norwegian den norske Mor & barn-undersøkelsen);NA: not applicable.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bjørn 2013 Study on systemic and inhaled corticosteroids, with no data on topical corticosteroids
Bjørn 2014 Study on systemic and inhaled corticosteroids, with no data on topical corticosteroids
Lin 2014 Case-control study on non-syndromic cleft of the lip and palate, but lacking data relevant to topical corticosteroids
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(Continued)
Zandi 2011 Case-control study on cleft lip and palate with no data on maternal exposure to specific drugs
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D A T A A N D A N A L Y S E S
Comparison 1. Topical corticosteroids versus no topical corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Assisted or cesarean delivery
(cohort study)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Congenital abnormality (cohort
study)
2 9512 Risk Ratio (IV, Random, 95% CI) 0.82 [0.34, 1.96]
3 Congenital abnormality
(case-control studies)
1 Odds Ratio (IV, Random, 95% CI) Totals not selected
4 Orofacial clefts (cohort studies) 2 Risk Ratio (Random, 95% CI) 1.12 [0.54, 2.33]
5 Cleft lip ± palate (cohort studies) 3 Risk Ratio (Random, 95% CI) Subtotals only
6 Cleft palate alone (cohort
studies)
3 Risk Ratio (Random, 95% CI) 1.31 [0.82, 2.11]
7 Orofacial clefts (case-control
studies)
8 Odds Ratio (Random, 95% CI) 1.20 [0.68, 2.13]
8 Cleft lip ± palate (case-control
studies)
8 Odds Ratio (Random, 95% CI) 1.52 [0.84, 2.75]
9 Cleft palate alone (case-control
studies)
8 Odds Ratio (Fixed, 95% CI) 1.20 [0.57, 2.54]
10 Hypospadias (case-control
studies)
2 Odds Ratio (Random, 95% CI) 0.45 [0.19, 1.09]
11 Low birth weight or foetal
growth restriction (cohort
studies)
4 Risk Ratio (Random, 95% CI) 1.08 [0.86, 1.36]
12 Preterm delivery (cohort study) 4 Risk Ratio (Random, 95% CI) 0.93 [0.81, 1.08]
13 Foetal death (cohort studies) 4 Risk Ratio (Random, 95% CI) 1.02 [0.60, 1.73]
14 Low Apgar score (cohort study) 2 Risk Ratio (Random, 95% CI) 0.84 [0.54, 1.31]
Comparison 2. Stratified analysis by corticosteroid potency
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Congenital abnormality (cohort
studies)
2 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Mild or moderate
corticosteroids
1 Risk Ratio (Random, 95% CI) 0.93 [0.23, 3.80]
1.2 Potent or very potent
corticosteroids
2 Risk Ratio (Random, 95% CI) 0.56 [0.14, 2.28]
2 Orofacial clefts (cohort studies) 2 Risk Ratio (Random, 95% CI) Subtotals only
2.1 Mild or moderate
corticosteroids
2 Risk Ratio (Random, 95% CI) 0.95 [0.40, 2.28]
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2.2 Potent or very potent
corticosteroids
2 Risk Ratio (Random, 95% CI) 1.50 [0.59, 3.82]
3 Low birth weight (cohort
studies)
4 Risk Ratio (Random, 95% CI) Subtotals only
3.1 Mild or moderate
corticosteroids
3 Risk Ratio (Random, 95% CI) 0.90 [0.74, 1.09]
3.2 Potent or very potent
corticosteroids
4 Risk Ratio (Random, 95% CI) 1.58 [0.96, 2.58]
4 Preterm delivery (cohort studies) 4 Risk Ratio (Random, 95% CI) Subtotals only
4.1 Mild or moderate
corticosteroids
3 Risk Ratio (Random, 95% CI) 0.88 [0.75, 1.03]
4.2 Potent or very potent
topical corticosteroids
4 Risk Ratio (Random, 95% CI) 1.05 [0.85, 1.31]
5 Foetal death (cohort studies) 3 Risk Ratio (Random, 95% CI) Subtotals only
5.1 Mild or moderate topical
corticosteroids
2 Risk Ratio (Random, 95% CI) 0.70 [0.64, 0.77]
5.2 Potent or very potent
topical corticosteroids
3 Risk Ratio (Random, 95% CI) 1.14 [0.69, 1.88]
6 Low Apgar score 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
6.1 Mild or moderate
corticosteroids
1 8756 Risk Ratio (IV, Random, 95% CI) 0.73 [0.45, 1.20]
6.2 Potent or very potent
corticosteroids
2 7514 Risk Ratio (IV, Random, 95% CI) 1.03 [0.52, 2.03]
Comparison 3. Sensitivity analysis after excluding poor quality studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Orofacial clefts (case-control
studies)
6 Odds Ratio (Random, 95% CI) 0.98 [0.53, 1.82]
2 Cleft lip ± palate (case-control
studies)
6 Odds Ratio (Random, 95% CI) 1.20 [0.73, 1.97]
3 Cleft palate alone (case-control
studies)
6 Odds Ratio (Fixed, 95% CI) 0.84 [0.37, 1.93]
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Analysis 1.1. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 1 Assisted
or cesarean delivery (cohort study).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 1 Assisted or cesarean delivery (cohort study)
Study or subgroup
Topical
corticos-
teroids Unexposed Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chi 2013 477/2658 1247/7246 1.04 [ 0.95, 1.15 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 477 (Topical corticosteroids), 1247 (Unexposed)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours corticosteroids Favours control
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Analysis 1.2. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 2
Congenital abnormality (cohort study).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 2 Congenital abnormality (cohort study)
Study or subgroup
Topical
corticos-
teroids Unexposed Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Mygind 2002 5/170 332/9263 100.0 % 0.82 [ 0.34, 1.96 ]
Mah 2007 0/23 0/56 Not estimable
Total (95% CI) 193 9319 100.0 % 0.82 [ 0.34, 1.96 ]
Total events: 5 (Topical corticosteroids), 332 (Unexposed)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours corticosteroids Favours control
Analysis 1.3. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 3
Congenital abnormality (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 3 Congenital abnormality (case-control studies)
Study or subgroup Case Control Odds Ratio Odds Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Czeizel 1997 (1) 38/20830 61/35727 1.07 [ 0.71, 1.60 ]
0.01 0.1 1 10 100
Favours corticosteroids Favours control
(1) Event refers to exposure to topical corticosteroids.
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Analysis 1.4. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 4 Orofacial
clefts (cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 4 Orofacial clefts (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Chi 2011a 0.0488 (0.3956) 88.1 % 1.05 [ 0.48, 2.28 ]
Chi 2013 0.613 (1.0757) 11.9 % 1.85 [ 0.22, 15.20 ]
Total (95% CI) 100.0 % 1.12 [ 0.54, 2.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours corticosteroids Favours control
Analysis 1.5. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 5 Cleft lip ±
palate (cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 5 Cleft lip palate (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Hviid 2011 0.3716 (0.1767) 1.45 [ 1.03, 2.05 ]
Chi 2011a 0.1823 (0.5619) 1.20 [ 0.40, 3.61 ]
Chi 2013 1.5657 (1.2241) 4.79 [ 0.43, 52.71 ]
Subtotal (95% CI) 0.0 [ 0.0, 0.0 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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Analysis 1.6. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 6 Cleft
palate alone (cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 6 Cleft palate alone (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Chi 2011a -0.0834 (0.5624) 18.6 % 0.92 [ 0.31, 2.77 ]
Hviid 2011 0.3716 (0.2738) 78.7 % 1.45 [ 0.85, 2.48 ]
Chi 2013 -0.1402 (1.4766) 2.7 % 0.87 [ 0.05, 15.70 ]
Total (95% CI) 100.0 % 1.31 [ 0.82, 2.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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Analysis 1.7. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 7 Orofacial
clefts (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 7 Orofacial clefts (case-control studies)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Czeizel 1997 0.4831 (0.3684) 19.7 % 1.62 [ 0.79, 3.34 ]
Pradat 2003 -0.6539 (0.5859) 13.3 % 0.52 [ 0.16, 1.64 ]
Ka¨ll n 2003 0.7 (0.4789) 16.2 % 2.01 [ 0.79, 5.15 ]
Edwards 2003 2.9258 (1.3638) 3.9 % 18.65 [ 1.29, 270.10 ]
Carmichael 2007 -0.5361 (0.7911) 9.2 % 0.59 [ 0.12, 2.76 ]
Skuladottir 2014a -1.7261 (1.0354) 6.2 % 0.18 [ 0.02, 1.35 ]
Skuladottir 2014c -0.0101 (0.4023) 18.5 % 0.99 [ 0.45, 2.18 ]
Skuladottir 2014b 0.8198 (0.6002) 12.9 % 2.27 [ 0.70, 7.36 ]
Total (95% CI) 100.0 % 1.20 [ 0.68, 2.13 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 13.45, df = 7 (P = 0.06); I2 =48%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours corticosteroids Favours control
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Analysis 1.8. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 8 Cleft lip ±
palate (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 8 Cleft lip palate (case-control studies)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Czeizel 1997 1.2357 (0.7481) 11.4 % 3.44 [ 0.79, 14.91 ]
Edwards 2003 2.608 (1.1248) 6.1 % 13.57 [ 1.50, 123.05 ]
Pradat 2003 -0.315 (0.6) 15.1 % 0.73 [ 0.23, 2.37 ]
Ka¨ll n 2003 0.8845 (0.5795) 15.7 % 2.42 [ 0.78, 7.54 ]
Carmichael 2007 -0.097 (0.7913) 10.5 % 0.91 [ 0.19, 4.28 ]
Skuladottir 2014b 0.6729 (0.6577) 13.5 % 1.96 [ 0.54, 7.11 ]
Skuladottir 2014c 0.1906 (0.4408) 20.8 % 1.21 [ 0.51, 2.87 ]
Skuladottir 2014a -1.3176 (1.0355) 6.9 % 0.27 [ 0.04, 2.04 ]
Total (95% CI) 100.0 % 1.52 [ 0.84, 2.75 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 10.76, df = 7 (P = 0.15); I2 =35%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 9 Cleft
palate alone (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 9 Cleft palate alone (case-control studies)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Czeizel 1997 0.5972 (1.4349) 7.1 % 1.82 [ 0.11, 30.25 ]
Edwards 2003 2.539 (1.1503) 11.0 % 12.67 [ 1.33, 120.73 ]
Ka¨ll n 2003 0.3077 (1.0017) 14.5 % 1.36 [ 0.19, 9.69 ]
Pradat 2003 -1.1048 (1.422) 7.2 % 0.33 [ 0.02, 5.38 ]
Carmichael 2007 -0.9492 (1.4558) 6.9 % 0.39 [ 0.02, 6.71 ]
Skuladottir 2014a -1.3621 (1.4389) 7.0 % 0.26 [ 0.02, 4.30 ]
Skuladottir 2014b 0.9708 (0.8593) 19.8 % 2.64 [ 0.49, 14.22 ]
Skuladottir 2014c -0.5108 (0.7425) 26.5 % 0.60 [ 0.14, 2.57 ]
Total (95% CI) 100.0 % 1.20 [ 0.57, 2.54 ]
Heterogeneity: Chi2 = 8.59, df = 7 (P = 0.28); I2 =18%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 10
Hypospadias (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 10 Hypospadias (case-control studies)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Czeizel 1997 -0.9816 (0.5809) 59.7 % 0.37 [ 0.12, 1.17 ]
Carmichael 2009 -0.5108 (0.7073) 40.3 % 0.60 [ 0.15, 2.40 ]
Total (95% CI) 100.0 % 0.45 [ 0.19, 1.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 11 Low
birth weight or foetal growth restriction (cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 11 Low birth weight or foetal growth restriction (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Mygind 2002 0.0633 (0.2162) 20.6 % 1.07 [ 0.70, 1.63 ]
Mah 2007 1.044 (0.4982) 5.1 % 2.84 [ 1.07, 7.54 ]
Chi 2011a 0.0912 (0.1604) 30.3 % 1.10 [ 0.80, 1.50 ]
Chi 2013 -0.0356 (0.1086) 44.0 % 0.97 [ 0.78, 1.19 ]
Total (95% CI) 100.0 % 1.08 [ 0.86, 1.36 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 4.66, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 12
Preterm delivery (cohort study).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 12 Preterm delivery (cohort study)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Mygind 2002 0.0322 (0.2012) 13.2 % 1.03 [ 0.70, 1.53 ]
Mah 2007 -0.7444 (1.53) 0.2 % 0.48 [ 0.02, 9.53 ]
Chi 2011a -0.1128 (0.0825) 78.2 % 0.89 [ 0.76, 1.05 ]
Chi 2013 0.1791 (0.252) 8.4 % 1.20 [ 0.73, 1.96 ]
Total (95% CI) 100.0 % 0.93 [ 0.81, 1.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.70, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 13 Foetal
death (cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 13 Foetal death (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Mygind 2002 0.9652 (0.6041) 14.6 % 2.63 [ 0.80, 8.58 ]
Mah 2007 0 (0) Not estimable
Chi 2011a -0.2584 (0.0429) 55.1 % 0.77 [ 0.71, 0.84 ]
Chi 2013 0.069 (0.331) 30.2 % 1.07 [ 0.56, 2.05 ]
Total (95% CI) 100.0 % 1.02 [ 0.60, 1.73 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 5.01, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Topical corticosteroids versus no topical corticosteroids, Outcome 14 Low
Apgar score (cohort study).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 1 Topical corticosteroids versus no topical corticosteroids
Outcome: 14 Low Apgar score (cohort study)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Chi 2013 -0.1731 (0.2261) 100.0 % 0.84 [ 0.54, 1.31 ]
Mah 2007 0 (0) Not estimable
Total (95% CI) 100.0 % 0.84 [ 0.54, 1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Stratified analysis by corticosteroid potency, Outcome 1 Congenital
abnormality (cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 2 Stratified analysis by corticosteroid potency
Outcome: 1 Congenital abnormality (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Mild or moderate corticosteroids
Mygind 2002 -0.073 (0.718) 100.0 % 0.93 [ 0.23, 3.80 ]
Subtotal (95% CI) 100.0 % 0.93 [ 0.23, 3.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 Potent or very potent corticosteroids
Mygind 2002 -0.58 (0.716) 100.0 % 0.56 [ 0.14, 2.28 ]
Mah 2007 0 (0) Not estimable
Subtotal (95% CI) 100.0 % 0.56 [ 0.14, 2.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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Analysis 2.2. Comparison 2 Stratified analysis by corticosteroid potency, Outcome 2 Orofacial clefts
(cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 2 Stratified analysis by corticosteroid potency
Outcome: 2 Orofacial clefts (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Mild or moderate corticosteroids
Chi 2011a -0.1985 (0.4882) 82.7 % 0.82 [ 0.31, 2.13 ]
Chi 2013 0.6723 (1.0681) 17.3 % 1.96 [ 0.24, 15.89 ]
Subtotal (95% CI) 100.0 % 0.95 [ 0.40, 2.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Potent or very potent corticosteroids
Chi 2011a 0.174 (0.5341) 80.0 % 1.19 [ 0.42, 3.39 ]
Chi 2013 1.3208 (1.0673) 20.0 % 3.75 [ 0.46, 30.35 ]
Subtotal (95% CI) 100.0 % 1.50 [ 0.59, 3.82 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 2.3. Comparison 2 Stratified analysis by corticosteroid potency, Outcome 3 Low birth weight
(cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 2 Stratified analysis by corticosteroid potency
Outcome: 3 Low birth weight (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Mild or moderate corticosteroids
Mygind 2002 -0.357 (0.717) 1.9 % 0.70 [ 0.17, 2.85 ]
Chi 2011a -0.1625 (0.1821) 29.7 % 0.85 [ 0.59, 1.21 ]
Chi 2013 -0.0726 (0.12) 68.4 % 0.93 [ 0.74, 1.18 ]
Subtotal (95% CI) 100.0 % 0.90 [ 0.74, 1.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Potent or very potent corticosteroids
Mygind 2002 0.207 (0.514) 15.3 % 1.23 [ 0.45, 3.37 ]
Mah 2007 1.044 (0.498) 16.0 % 2.84 [ 1.07, 7.54 ]
Chi 2011a 0.7324 (0.203) 33.5 % 2.08 [ 1.40, 3.10 ]
Chi 2013 0.035 (0.1802) 35.2 % 1.04 [ 0.73, 1.47 ]
Subtotal (95% CI) 100.0 % 1.58 [ 0.96, 2.58 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 8.57, df = 3 (P = 0.04); I2 =65%
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Chi2 = 4.32, df = 1 (P = 0.04), I2 =77%
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Analysis 2.4. Comparison 2 Stratified analysis by corticosteroid potency, Outcome 4 Preterm delivery
(cohort studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 2 Stratified analysis by corticosteroid potency
Outcome: 4 Preterm delivery (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Mild or moderate corticosteroids
Mygind 2002 0.039 (0.314) 6.8 % 1.04 [ 0.56, 1.92 ]
Chi 2011a -0.1544 (0.0889) 85.1 % 0.86 [ 0.72, 1.02 ]
Chi 2013 0.0064 (0.2881) 8.1 % 1.01 [ 0.57, 1.77 ]
Subtotal (95% CI) 100.0 % 0.88 [ 0.75, 1.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
2 Potent or very potent topical corticosteroids
Mygind 2002 -0.0057 (0.313) 12.4 % 0.99 [ 0.54, 1.84 ]
Mah 2007 -0.76 (1.538) 0.5 % 0.47 [ 0.02, 9.53 ]
Chi 2011a 0.0434 (0.1234) 79.7 % 1.04 [ 0.82, 1.33 ]
Chi 2013 0.2925 (0.406) 7.4 % 1.34 [ 0.60, 2.97 ]
Subtotal (95% CI) 100.0 % 1.05 [ 0.85, 1.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 1.71, df = 1 (P = 0.19), I2 =42%
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Analysis 2.5. Comparison 2 Stratified analysis by corticosteroid potency, Outcome 5 Foetal death (cohort
studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 2 Stratified analysis by corticosteroid potency
Outcome: 5 Foetal death (cohort studies)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Mild or moderate topical corticosteroids
Chi 2011a -0.3538 (0.0472) 98.6 % 0.70 [ 0.64, 0.77 ]
Chi 2013 -0.2084 (0.3976) 1.4 % 0.81 [ 0.37, 1.77 ]
Subtotal (95% CI) 100.0 % 0.70 [ 0.64, 0.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 7.51 (P < 0.00001)
2 Potent or very potent topical corticosteroids
Mah 2007 0 (0) Not estimable
Chi 2011a -0.0061 (0.0564) 76.9 % 0.99 [ 0.89, 1.11 ]
Chi 2013 0.5994 (0.4479) 23.1 % 1.82 [ 0.76, 4.38 ]
Subtotal (95% CI) 100.0 % 1.14 [ 0.69, 1.88 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 1.80, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 3.50, df = 1 (P = 0.06), I2 =71%
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Analysis 2.6. Comparison 2 Stratified analysis by corticosteroid potency, Outcome 6 Low Apgar score.
Review: Safety of topical corticosteroids in pregnancy
Comparison: 2 Stratified analysis by corticosteroid potency
Outcome: 6 Low Apgar score
Study or subgroup
Topical
corticos-
teroids Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Mild or moderate corticosteroids
Chi 2013 19/1993 88/6763 100.0 % 0.73 [ 0.45, 1.20 ]
Subtotal (95% CI) 1993 6763 100.0 % 0.73 [ 0.45, 1.20 ]
Total events: 19 (Topical corticosteroids), 88 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
2 Potent or very potent corticosteroids
Mah 2007 0/23 0/56 Not estimable
Chi 2013 9/672 88/6763 100.0 % 1.03 [ 0.52, 2.03 ]
Subtotal (95% CI) 695 6819 100.0 % 1.03 [ 0.52, 2.03 ]
Total events: 9 (Topical corticosteroids), 88 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Chi2 = 0.63, df = 1 (P = 0.43), I2 =0.0%
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Analysis 3.1. Comparison 3 Sensitivity analysis after excluding poor quality studies, Outcome 1 Orofacial
clefts (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 3 Sensitivity analysis after excluding poor quality studies
Outcome: 1 Orofacial clefts (case-control studies)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Pradat 2003 -0.6539 (0.5859) 17.3 % 0.52 [ 0.16, 1.64 ]
Ka¨ll n 2003 0.7 (0.4789) 21.5 % 2.01 [ 0.79, 5.15 ]
Carmichael 2007 -0.5361 (0.7911) 11.6 % 0.59 [ 0.12, 2.76 ]
Skuladottir 2014c -0.0101 (0.4023) 25.2 % 0.99 [ 0.45, 2.18 ]
Skuladottir 2014a -1.7261 (1.0354) 7.6 % 0.18 [ 0.02, 1.35 ]
Skuladottir 2014b 0.8198 (0.6002) 16.8 % 2.27 [ 0.70, 7.36 ]
Total (95% CI) 100.0 % 0.98 [ 0.53, 1.82 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 8.44, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Sensitivity analysis after excluding poor quality studies, Outcome 2 Cleft lip ±
palate (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 3 Sensitivity analysis after excluding poor quality studies
Outcome: 2 Cleft lip palate (case-control studies)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Ka¨ll n 2003 0.8845 (0.5795) 18.9 % 2.42 [ 0.78, 7.54 ]
Pradat 2003 -0.315 (0.6) 17.6 % 0.73 [ 0.23, 2.37 ]
Carmichael 2007 -0.097 (0.7913) 10.1 % 0.91 [ 0.19, 4.28 ]
Skuladottir 2014a -1.3176 (1.0355) 5.9 % 0.27 [ 0.04, 2.04 ]
Skuladottir 2014b 0.6729 (0.6577) 14.7 % 1.96 [ 0.54, 7.11 ]
Skuladottir 2014c 0.1906 (0.4408) 32.7 % 1.21 [ 0.51, 2.87 ]
Total (95% CI) 100.0 % 1.20 [ 0.73, 1.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.93, df = 5 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Sensitivity analysis after excluding poor quality studies, Outcome 3 Cleft palate
alone (case-control studies).
Review: Safety of topical corticosteroids in pregnancy
Comparison: 3 Sensitivity analysis after excluding poor quality studies
Outcome: 3 Cleft palate alone (case-control studies)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ka¨ll n 2003 0.3077 (1.0017) 17.8 % 1.36 [ 0.19, 9.69 ]
Pradat 2003 -1.1048 (1.422) 8.8 % 0.33 [ 0.02, 5.38 ]
Carmichael 2007 -0.9492 (1.4558) 8.4 % 0.39 [ 0.02, 6.71 ]
Skuladottir 2014a -1.3621 (1.4389) 8.6 % 0.26 [ 0.02, 4.30 ]
Skuladottir 2014c -0.5108 (0.7425) 32.3 % 0.60 [ 0.14, 2.57 ]
Skuladottir 2014b 0.9708 (0.8593) 24.1 % 2.64 [ 0.49, 14.22 ]
Total (95% CI) 100.0 % 0.84 [ 0.37, 1.93 ]
Heterogeneity: Chi2 = 3.61, df = 5 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Potency of topical corticosteroidsa
Mild
Hydrocortisone 0.10%-2.50%
Hydrocortisone acetate 0.1%
Fluocinolone acetonide 0.0025%
Moderate
Alclometasone dipropionate 0.05%
Betamethasone valerate 0.025%
Clobetasone butyrate 0.05%
Fludroxycortide (flurandrenolone) 0.0125%
Fluocinolone acetonide 0.00625%
Fluocortolone 0.25%
Potent
Hydrocortisone butyrate 0.10%
Beclometasone dipropionate 0.025%
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Table 1. Potency of topical corticosteroidsa (Continued)
Betamethasone valerate 0.10%-0.12%
Fluocinolone acetonide 0.025%
Fluprednidene acetate 0.10%
Fluocinonide 0.05%
Diflucortolone valerate 0.10%
Fluticasone propionate 0.005%-0.05%
Mometasone furoate 0.10%
Triamcinolone acetonide 0.10%
Betamethasone dipropionate 0.05%-0.064%
Very potent
Diflucortolone valerate 0.30%
Halcinonide 0.10%
Clobetasol propionate 0.05%
aThe listed potency of the topical corticosteroid preparations is according to the British National Formulary (Mehta 2006).
Table 2. Contact with manufacturers
Manufacturer Products Date of contact letter
sent
Date of receiving reply Reply
GlaxoSmithKline Hydrocortisone,
beclometasone dipro-
pionate, betamethasone
valerate, clobetasol pro-
pionate, clobetasone bu-
tyrate, fluticasone propi-
onate
15 August 2008 29 August 2008 “Unfortunately we are
not aware of any data...”
Astellas Hydrocortisone, hydro-
cortisone butyrate
15 August 2008 - -
Schering-Plough Alclometasone dipro-
pionate, betamethasone
dipropionate, mometa-
sone furoate
15 August 2008 26 August 2008 An extensive
search through Scher-
ing-Plough UK Phar-
macovigilance Database
found 3 cases of preg-
nancy while taking/us-
ing betamethasone
dipropionate, mometa-
sone furoate, but none
reported any follow-up
or outcomes
No relevant clinical stud-
ies done by them
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Table 2. Contact with manufacturers (Continued)
Meadow Diflucortolone valerate,
fluocortolone
15 August 2008 - -
Typharm Fludroxycortide (fluran-
drenolone)
15 August 2008 - -
GP Pharma
(Derma UK)
Fluocinolone acetonide,
fluocinonide
15 August 2008 - -
Ferndale Fluprednidene acetate,
hydrocortisone butyrate,
hydrocortisone acetate
15 August 2008 - -
Bristol-Myers Squibb Halcinonide,
triamcinolone acetonide
15 August 2008 5 September 2008 Did not provide any rel-
evant data but SPC for
triamcinolone acetonide
injection
TARO Diflorasone diacetate, al-
clometasone dipro-
pionate, amcinonide, be-
tamethasone dipro-
pionate, betamethasone
valerate, clobetasol pro-
pionate, desonide, des-
oximetasone, fluocinon-
ide, hydrocortisone,
hydrocortisone butyrate,
hydrocortisone valerate,
mometasone furoate, tri-
amcinolone acetonide
15 August 2008 - -
Intendis Hydrocortisone
aceponate
15 August 2008 - -
Dermik (Sanofi-Aventis
US)
Diflorasone diacetate,
prednicarbate
15 August 2008 - -
SPC: statistical process control.
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A P P E N D I C E S
Appendix 1. Skin Group Specialised Register strategy
((“Adrenal Cortex Hormone*” or “topical corticosteroid*“ or “topical glucocorticoid*” or “topical steroid*” or “topical corticoid*”
or Hydrocortisone or cortisol or “Fluocinolone Acetonide” or “alclometasone dipropionate” or Betamethasone or clobetasone or
flurandrenolone or fludroxycortide or Fluocortolone or beclometasone or Fluprednidene or Fluocinonide or diflucortolone or fluticasone
or mometasone or triamcinolone or halcinonide or clobetasol or diflorasone or amcinonide or desoximetasone or desonide or cortisone
or methylprednisolone or prednisolone or budesonide or fluclorolone or flumethasone or prednicarbate or halobetasol or ulobetasol or
“clocortolone pivalate” or fluocortin or halometasone) and (pregnan* or abnormalit* or obstetric* or labor or labour or fetal or foetal
or fetus or foetus or birth or congenital or complication* or cleft or orofacial or teratogen* or toxic* or “birth weight” or birthweight
or “body height” or “body length” or “crown rump length” or “intrauterine growth retardation” or “embryonic development” or “apgar
score*” or prematurity or “premature birth” or “preterm delivery”)):ti,ab
Appendix 2. Pregnancy and Childbirth Group Specialised Register strategy
The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major conferences;
5. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings,
and the list of journals reviewed via the current awareness service can be found in the ’Specialized Register’ section within the editorial
information about the Cochrane Pregnancy and Childbirth Group.
Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-
ordinator searches the register for each review using the topic list rather than keywords.
Appendix 3. CENTRAL (Cochrane Library) strategy
#1 (corticosteroid* or steroid* or *cortisone or glucocorticoid* or *methasone or *metasone or *cinonide or *nisolone or *cinolone
or *betasone or *betasol or corticoid or flurandrenolone or *cortolone or fluprednidene or fluticasone or fluclorolone or diflorasone
or *desonide or fluprednidene or prednicarbate or fluocinolone or triamcinolone or halcinonide or ulobetasol or fluocortin):ti,ab and
(topical or absorption or skin):ti,ab
#2 MeSH descriptor: [Steroids] explode all trees
#3 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees
#4 (pregnan* or obstetric* or labor or labour or fetal or foetal or fetus or foetus or birth or congenital or cleft or teratogen* or toxic*
or ”birth weight“ or birthweight or ”body height“ or ”body length“ or ”crown rump length“ or ”intrauterine growth retardation“ or
”embryonic development“ or ”apgar score“ or prematurity or ”premature birth“ or ”preterm delivery“):ti,ab
#5 MeSH descriptor: [Pregnancy] explode all trees
#6 MeSH descriptor: [Abnormalities, Drug-Induced] explode all trees
#7 MeSH descriptor: [Teratogens] explode all trees
#8 MeSH descriptor: [Pregnancy Complications] explode all trees
#9 MeSH descriptor: [Fetal Growth Retardation] explode all trees
#10 MeSH descriptor: [Cleft Lip] explode all trees
#11 MeSH descriptor: [Cleft Palate] explode all trees
#12 MeSH descriptor: [Congenital Abnormalities] explode all trees
#13 MeSH descriptor: [Infant, Premature] explode all trees
#14 (topical or absorption or skin):ti,ab
#15 #2 and #14
#16 #3 and #14
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#17 #1 or #15 or #16
#18 {or #4-#13}
#19 #17 and #18
Appendix 4. MEDLINE (Ovid) strategy
1. exp Cohort Studies/
2. cohort$.tw.
3. controlled clinical trial.pt.
4. Epidemiologic Methods/
5. limit 4 to yr=1966-1989
6. exp case-control studies/
7. (case$ and control$).tw.
8. or/1-3,5-7
9. randomized controlled trial.pt.
10. controlled clinical trial.pt.
11. randomized.ab.
12. placebo.ab.
13. clinical trials as topic.sh.
14. randomly.ab.
15. trial.ti.
16. 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp animals/ not humans.sh.
18. 16 not 17
19. 8 or 18
20. exp Adrenal Cortex Hormones/ and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
21. exp Glucocorticoids/ and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
22. (topical corticosteroid$ or topical glucocorticoid$ or topical steroid$ or topical corticoid$).ti,ab.
23. exp Hydrocortisone/ and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
24. (hydrocortisone or cortisol).ti,ab. and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
25. hydrocortisone butyrate.ti,ab.
26. hydrocortisone valerate.ti,ab.
27. hydrocortisone aceponate.ti,ab.
28. exp Fluocinolone Acetonide/ and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
29. fluocinolone acetonide.ti,ab. and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
30. alclometasone dipropionate.ti,ab.
31. (exp Betamethasone/ or betamethasone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
32. exp Betamethasone 17-Valerate/ or ”betamethasone adj2 valerate“.ti,ab.
33. betamethasone dipropionate.ti,ab.
34. clobetasone.ti,ab.
35. exp Flurandrenolone/ or (flurandrenolone or fludroxycortide).ti,ab.
36. (exp Fluocortolone/ or fluocortolone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/)
37. (exp Beclomethasone/ or beclometasone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
38. fluprednidene.ti,ab.
39. exp Fluocinonide/ or fluocinonide.ti,ab.
40. exp Diflucortolone/ or diflucortolone.ti,ab.
41. fluticasone.ti,ab. and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
42. mometasone.ti,ab. and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
43. (exp Triamcinolone/ or exp Triamcinolone Acetonide/ or triamcinolone.ti,ab.) and (exp Administration, Topical/ or expOintments/
or Dermatologic Agents/)
44. exp Halcinonide/ or halcinonide.ti,ab.
45. exp Clobetasol/ or clobetasol.ti,ab.
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46. diflorasone.ti,ab.
47. amcinonide.ti,ab.
48. exp Desoximetasone/ or desoximetasone.ti,ab.
49. exp Desonide/ or desonide.ti,ab.
50. (exp Cortisone/ or cortisone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
51. (exp Methylprednisolone/ or methylprednisolone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/ or Dermatologic
Agents/)
52. methylprednisolone aceponate.ti,ab.
53. (exp Prednisolone/ or prednisolone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
54. (exp Budesonide/ or budesonide.ti,ab.) and (exp Ointments/ or Dermatologic Agents/)
55. fluclorolone.ti,ab.
56. (exp Flumethasone/ or flumethasone.ti,ab.) and (exp Administration, Topical/ or exp Ointments/ or Dermatologic Agents/)
57. flumethasone pivalate.ti,ab.
58. prednicarbate.ti,ab.
59. (halobetasol or ulobetasol).ti,ab.
60. clocortolone pivalate.ti,ab.
61. fluocortin.ti,ab.
62. halometasone.ti,ab.
63. or/20-62
64. ae.fs.
65. to.fs.
66. co.fs.
67. po.fs.
68. or/64-67
69. exp Pregnancy/
70. pregnan$4.ti,ab.
71. 69 or 70
72. exp Drug Toxicity/ or toxic$5.ti,ab.
73. exp Abnormalities, Drug-Induced/ or exp Abnormalities/
74. 72 or 73
75. 71 and 74
76. exp Teratogens/ or teratogen$.ti,ab.
77. exp Obstetric Labor Complications/ or exp Pregnancy Complications/ or exp Pregnancy Outcome/
78. obstetric$ outcome$.ti,ab.
79. ((obstetric$ or labour or labor) adj2 complication$).ti,ab.
80. ((fetal adj outcome$) or (foetal adj outcome$)).ti,ab.
81. exp Birth Weight/ or (birth weight or birthweight).ti,ab.
82. (exp Body Height/ or body height.ti,ab. or body length.ti,ab.) and Infant/
83. exp Crown-Rump Length/ or crown rump length.ti,ab.
84. exp Fetal Growth Retardation/ or intrauterine growth retardation.ti,ab.
85. exp Fetal Development/
86. exp Embryonic Development/
87. exp Fetal Diseases/
88. exp Apgar Score/ or Apgar score$.ti,ab.
89. exp Cleft Palate/ or exp Cleft Lip/ or (cleft palate or cleft lip or oral cleft or orofacial cleft).ti,ab.
90. (congenital anomal$ or congenital malformation$ or inborn error$ or congenital abnormalit$).ti,ab.
91. exp Congenital Abnormalities/ or exp Genetic Diseases, Inborn/
92. ((congenital or hereditary or neonatal) adj2 (disease$ or abnormalit$)).ti,ab.
93. exp Heart Defects, Congenital/ or (congenital heart disease$ or congenital heart defect$).ti,ab.
94. exp Obstetric Labor, Premature/ or exp Premature Birth/ or preterm delivery.ti,ab.
95. exp Infant, Premature/ or prematurity.ti,ab.
96. or/75-95
97. 63 and 68
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98. 19 and 96 and 97
NB Lines 1-8 are the BMJ Clinical Evidence MEDLINE (Ovid) cohort and case-control search filter.
Appendix 5. EMBASE (Ovid) strategy
1. crossover procedure.sh.
2. double-blind procedure.sh.
3. single-blind procedure.sh.
4. (crossover$ or cross over$).tw.
5. placebo$.tw.
6. (doubl$ adj blind$).tw.
7. allocat$.tw.
8. trial.ti.
9. randomized controlled trial.sh.
10. random$.tw.
11. or/1-10
12. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
13. human/ or normal human/
14. 12 and 13
15. 12 not 14
16. 11 not 15
17. exp corticosteroid/ and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/)
18. exp glucocorticoid/ and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/)
19. (topical corticosteroid$ or topical glucocorticoid$ or topical steroid$ or topical corticoid$).ti,ab.
20. exp Hydrocortisone/ and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/)
21. (hydrocortisone or cortisol or hydrocortisone acetate).ti,ab. and (exp ointment/ or exp topical drug administration/ or exp derma-
tological agent/)
22. (hydrocortisone butyrate or hydrocortisone valerate or hydrocortisone aceponate).ti,ab.
23. exp hydrocortisone butyrate/ or exp hydrocortisone valerate/ or exp hydrocortisone aceponate/
24. exp fluocinolone acetonide/ and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/)
25. fluocinolone acetonide.ti,ab. and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/)
26. alclometasone dipropionate.ti,ab. or exp alclometasone dipropionate/
27. (exp betamethasone/ or betamethasone.ti,ab.) and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/
)
28. exp betamethasone dipropionate/ or exp betamethasone valerate/
29. (betamethasone dipropionate or ”betametasone adj2 valerate“).ti,ab.
30. clobetasone butyrate/ or exp clobetasone/ or clobetasone.ti,ab.
31. flurandrenolone.ti,ab. or exp fludroxycortide/ or fludroxycortide.ti,ab.
32. (fluocortolone.ti,ab. or exp fluocortolone/) and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/)
33. (beclomethasone.ti,ab. or exp beclometasone/) and (exp ointment/ or exp topical drug administration/ or exp dermatological agent/
)
34. exp fluprednidene/ or fluprednidene.ti,ab.
35. exp Fluocinonide/ or fluocinonide.ti,ab.
36. exp diflucortolone/ or diflucortolone.ti,ab.
37. (fluticasone.ti,ab. or exp fluticasone/ or exp fluticasone propionate/) and (exp ointment/ or exp topical drug administration/ or exp
dermatological agent/)
38. (mometasone.ti,ab. or exp mometasone furoate/) and (exp ointment/ or exp topical drug administration/ or exp dermatological
agent/)
39. (triamcinolone.ti,ab. or exp triamcinolone/ or exp triamcinolone acetonide/) and (exp ointment/ or exp topical drug administration/
or exp dermatological agent/)
40. halcinonide.ti,ab. or exp halcinonide/
41. exp clobetasol propionate/ or clobetasol.ti,ab. or exp clobetasol/ or exp clobetasol butyrate/
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42. exp diflorasone diacetate/ or exp diflorasone/ or diflorasone.ti,ab.
43. amcinonide.ti,ab. or exp amcinonide/
44. desoximetasone.ti,ab. or exp desoximetasone/
45. exp Desonide/ or desonide.ti,ab.
46. (cortisone.ti,ab. or exp cortisone acetate/ or exp cortisone/) and (exp ointment/ or exp topical drug administration/ or exp
dermatological agent/)
47. (exp methylprednisolone/ or methylprednisolone.ti,ab. or exp methylprednisolone acetate/) and (exp ointment/ or exp topical drug
administration/ or exp dermatological agent/)
48. methylprednisolone aceponate.ti,ab. or exp methylprednisolone aceponate/
49. (exp prednisolone/ or prednisolone.ti,ab. or exp prednisolone acetate/) and (exp ointment/ or exp topical drug administration/ or
exp dermatological agent/)
50. (exp Budesonide/ or budesonide.ti,ab.) and (exp ointment/ or dermatological agent/)
51. exp fluclorolone/ or fluclorolone.ti,ab.
52. (flumetasone.ti,ab. or exp flumetasone/ or flumethasone.ti,ab.) and (exp ointment/ or exp topical drug administration/ or exp
dermatological agent/)
53. flumetasone pivalate.ti,ab. or exp flumetasone pivalate/
54. prednicarbate.ti,ab. or exp prednicarbate/
55. (ulobetasol or halobetasol).ti,ab.
56. clocortolone pivalate.ti,ab. or exp clocortolone pivalate/
57. exp fluocortin/ or fluocortin.ti,ab.
58. halometasone.ti,ab. or exp halometasone/
59. or/17-58
60. (ae or to).fs.
61. 59 and 60
62. exp Pregnancy/ or pregnan$4.ti,ab.
63. exp teratogenic agent/ or teratogen$.ti,ab.
64. (exp Drug Toxicity/ or toxic$5.ti,ab.) and exp Pregnancy/
65. exp labor complication/ or exp Pregnancy Complication/ or exp Pregnancy Outcome/
66. obstetric$ outcome$.ti,ab.
67. ((obstetric$ or labour or labor) adj2 complication$).ti,ab.
68. ((fetal adj outcome$) or (foetal adj outcome$)).ti,ab.
69. exp Birth Weight/ or (birth weight or birthweight).ti,ab.
70. exp Body Height/ or body height.ti,ab. or body length.ti,ab.
71. exp Crown-Rump Length/ or crown-rump length.ti,ab.
72. exp intrauterine growth retardation/ or intrauterine growth retardation.ti,ab.
73. exp fetus development/ or exp embryo development/ or exp fetus disease/
74. exp Apgar Score/ or Apgar score$.ti,ab.
75. exp Cleft Palate/ or exp Cleft Lip/ or (cleft palate or cleft lip or oral cleft or orofacial cleft).ti,ab.
76. exp Abnormalities, Drug-Induced/ or exp Abnormalities/
77. ”Congenital, Hereditary, and Neonatal Diseases and Abnormalities“/
78. (congenital anomal$ or congenital malformation or inborn error or congenital abnormalit$).ti,ab.
79. exp congenital malformation/ or exp ”inborn error of metabolism“/
80. ((congenital or hereditary or neonatal) adj2 (disease$ or abnormalit$)).ti,ab.
81. exp congenital heart malformation/ or congenital heart disease.ti,ab.
82. exp premature labor/ or preterm delivery.ti,ab.
83. exp prematurity/ or prematurity.ti,ab.
84. or/62-83
85. 16 and 61 and 84
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Appendix 6. LILACS strategy
(pregnan$ or embarazo or baby or bebe or obstetric$ or foetal or congenital or cleft or hendidura or teratogen$ or apgar or prematur$)
and (steroid$ or esteroide$ or corticosteroid$ or corticoesteroide$ or corticoid$ or glucocorticoid$)
Appendix 7. ISRCTN registry strategy
Public title: pregnancy topical steroid (0)
Public title: pregnancy topical corticosteroid (0)
Public title: pregnant topical steroid (0)
Public title: pregnant topical corticosteroid (0)
Appendix 8. US National Institutes of Health Ongoing Trials Register strategy
”pregnancy“ AND ”topical steroid“ (0)
”pregnancy“ AND ”topical corticosteroid“ (2)
”pregnant“ AND ”topical steroid“ (1)
”pregnant“ AND ”topical corticosteroid“ (0)
Appendix 9. Australian New Zealand Clinical Trials Registry strategy
pregnancy topical steroid (0)
pregnancy topical corticosteroid (1)
pregnant topical steroid (0)
pregnant topical corticosteroid (0)
Appendix 10. World Health Organization International Clinical Trials Registry platform strategy
pregnancy AND topical steroid (0)
pregnancy AND topical corticosteroid (0)
pregnant AND topical steroid (0)
pregnant AND topical corticosteroid (0)
Appendix 11. EU Clinical Trials Register strategy
pregnancy AND topical steroid (8)
pregnancy AND topical corticosteroid (11)
pregnant AND topical steroid (1)
pregnant AND topical corticosteroid (0)
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WH A T ’ S N E W
Last assessed as up-to-date: 10 July 2015.
Date Event Description
20 October 2015 New search has been performed We included 7 new observational studies in this update
20 October 2015 New citation required but conclusions have not
changed
There has been no significant alteration to the conclu-
sions of the previous version of the review
C O N T R I B U T I O N S O F A U T H O R S
CC was the contact person with the editorial base, co-ordinated contributions from the coauthors, and wrote the final draft of the
review.
CC and SW screened papers against eligibility criteria.
CC obtained data on ongoing and unpublished studies.
CC and SW appraised the quality of papers.
CC extracted data for the review and sought additional information about papers.
CC entered data into RevMan.
CC, SW, GK, and FW analysed and interpreted data.
CC worked on the Methods sections.
CC drafted the clinical sections of the background and responded to the clinical comments of the referees.
CC responded to the methodology and statistics comments of the referees.
EDwas the consumer coauthor and checked the review for readability and clarity, as well as ensuring outcomes are relevant to consumers.
CB extracted data from two studies (Chi 2011a; Chi 2013), independently from the investigators of those two studies who are also
authors of this Cochrane review.
CC is the guarantor of the update.
Disclaimer
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Skin
Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health.
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S O U R C E S O F S U P P O R T
Internal sources
• Chang Gung Memorial Hospital, Chiayi, Taiwan.
External sources
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between protocol and review
We originally planned to express all dichotomous outcomes as risk ratios (RR) and 95% confidence intervals (CI). However, we obtained
some data from case-control studies, and we decided to retain them as OR with 95% CIs.
We originally planned to analyse major and minor congenital abnormalities separately but did not find any studies that reported them
separately. Therefore, we grouped the two outcomes together.
We did not originally plan ’Summary of Findings’ tables, but we thought it important and included them in this review.
GRADE has been adopted postprotocol to rate the quality of evidence.
Differences between protocol and this review update
Types of studies: In the protocol we said, ”We will not deliberately examine all trials of topical corticosteroids to find out if they
contained any pregnant women, or contact the original researchers to enquire if any women became pregnant during the trial.“ In the
review, we simplified this to ”We did not include RCTs recruiting pregnant women only as a subset.“ and we have retained this phrase
for this update.
Types of outcome measures: For this update of the review, we expanded the scope of the outcome ’stillbirth’ to ’foetal death’.
Search methods for identification of studies, Electronic searches: For this update of the review, we decided not to search Cumulative
Index to Nursing & Allied Health (CINAHL), British Nursing Index (BNI), or BIOSIS Previews because they did not produce any
useful results in the 2009 searches. We updated the list of trials registers we searched to match current Skin Group searching practice.
Searching other resources, Reference lists: To increase the sensitivity of our search, we also used SCI-EXPANDED on 21 July 2014 to
identify and scan the articles that had cited the included studies, which we had not planned at the protocol stage.
Data collection and analysis, Assessment of risk of bias in included studies: We omitted from the protocol that we planned to assess
’selective reporting’ in any RCTs. We will include this is future updates of this review if we find any RCTs that we can include.
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Differences between the original 2009 review and this update
Types of outcome measures, Primary outcomes: The following phrase was in the review but has been moved to the Results, Included
studies, Outcomes: ”We analysed orofacial cleft separately as it is an expected possible associated outcome. When detailed data were
available, we further analysed the two categories of orofacial cleft (i.e., cleft lip with or without cleft palate, and isolated cleft palate),
separately, because they are considered aetiologically distinct (Stanier 2004).“
Search methods for identification of studies, Electronic searches: For this update, we revised the search strategies for the Skin Group
Specialised Register, CENTRAL, MEDLINE, EMBASE, and LILACS to increase the sensitivity of searching cohort and case-control
studies. We did not search the EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/) in the original 2009 review, but for
this update, we did search it in order to increase the sensitivity of our search.
Searching other resources, Handsearching: In the original 2009 review, we searched two electronic conference proceedings databases.
When we updated this review, we decided this handsearching was less valuable than handsearching CC’s private collection of literature
relevant to the review topic.
Searching other resources, Correspondence: In the protocol, we said ”We shall correspond with the original researchers to identify
unpublished or ongoing trials and observational studies“, but while conducting the previous review, we requested relevant studies from
11 pharmaceutical companies that had introduced an original topical corticosteroid product (Table 2). Only three companies replied
to us, and all of them were unaware of any relevant data. For this update, we did not correspond with pharmaceutical companies.
Data collection and analysis: we explained our inclusion of ’Summary of findings’ tables in this review update.
Data collection and analysis, Assessment of risk of bias in included studies, RCTs: we did not find any RCTs so could not evaluate risk
of bias.
Data collection and analysis, Assessment of risk of bias in included studies, Non-randomised studies: We added another assessment for
cohort studies, ’Demonstration that outcome of interest was not present at start of study’, as well as another assessment for case-control
studies, ’Representativeness of the cases’, and we omitted ’... selection of the cases’ to bring it in line with the original NOS checklist.
Data collection and analysis, Measures of treatment effect: We moved the following text from the Methods to the Results, Included
studies, Outcomes: ”Edwards 2003 used a classification of orofacial cleft different from ours and divided the cases as cleft palate ± lip
and isolated cleft palate (see Effects of interventions). We thus used the published data to calculate the case number of cleft lip with or
without cleft palate and used Review Manager software (RevMan 2014) to recalculate all the crude ORs and 95% CIs for consistency.“
Data collection and analysis, Unit of analysis issues: We changed this from the plan in the protocol and review to meet the recommen-
dations provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Data collection and analysis, Dealing with missing data: We could not carry out our plans due to the lack of relevant RCTs.
Data collection and analysis, Assessment of reporting biases: The small number of studies identified and the heterogeneity among them
meant that it was not possible to use funnel plots to test for publication bias.
Data collection and analysis, Subgroup analysis and investigation of heterogeneity:We did not analyse our originally planned subgroups
of maternal skin conditions (polymorphic eruption of pregnancy, pemphigoid gestationis, etc.) and maternal ages because the data were
unavailable from the investigators of studies included in this review.
Results, Effects of interventions: We conducted a post hoc analysis of steroid dose potencies.
Results, Effects of interventions: We made a decision to report hypospadias separately because it was reported in the newly included
study Skuladottir 2014a, which was an extension of the Carmichael 2007 study on orofacial cleft.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Abnormalities, Drug-Induced [etiology]; Administration, Topical; Adrenal Cortex Hormones [administration & dosage; ∗adverse
effects]; Birth Weight [drug effects]; Case-Control Studies; Cleft Lip [chemically induced]; Cleft Palate [chemically induced]; Cohort
Studies; Dermatologic Agents [administration & dosage; ∗adverse effects]; Pregnancy Complications [∗drug therapy]; Premature Birth
[chemically induced]; Skin Pigmentation
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MeSH check words
Female; Humans; Pregnancy
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